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URINARY BILE ACID INDICES AS PROGNOSTIC BIOMARKERS FOR THE
COMPLICATIONS OF LIVER DISEASES
Wenkuan Li,M.S.
University of Nebraska Medical Center, 2021

Supervisor: Yazen Alnouti, Ph.D.

Hepatobilary diseases cause the accumulation of toxic bile acids (BA) in the liver,
blood, and other tissues, which may lead to an unfavorable prognosis. In this study,
we compared the urinary BA profile in 257 patients with hepatobilary diseases during
a 7-year follow-up period. We investigated the use of the urinary BA profile to
develop logistic regression models to predict the prognosis of hepatobiliary diseases
in terms of developing disease-related complications, especially for ascites. The
urinary BA profile was characterized by calculating BA indices, which quantify the
composition, metabolism, hydrophilicity, and toxicity of the BA profile. All patients
had high total and individual BA concentrations. The percentages of primary BA
(CDCA and LCA) were high, while the percentages of secondary BA (MDCA and
DCA) were low in patients.

BA indices had lower inter- and intra-individual

variability than absolute total and individual BA concentrations.

The changes of the

BA indices were associated with the probability of developing ascites in the entire
liver-patient population using logistic regression analysis. BA indices were proved
as prognostic biomarkers for hepatobilary diseases.
We have developed and validated a prognosis model based on BA indices to
predict the prognosis of ascites in the entire liver-patient population.

Other models,
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including non-BA, original MELD, and mixed BA and non-BA models, were also
developed to compare their performance with our BA model.

Overall, the mixed BA

and non-BA model was the most accurate based on Akaike information criterion
(AIC) and receiver operating characteristic (ROC) analyses.

The mixed BA and

non-BA had lower AIC values indicating a smaller error of distribution and a better
trade-off between goodness of fit vs. degrees of freedom. Moreover, the mixed BA
and non-BA model had highest area under the ROC curve (AUC) values indicating
higher accuracy than other models. One application of the mixed BA and non-BA
model could be used to predict the development of ascites in patients diagnosed with
liver-disease at early stages of intervention, such as liver transplantation.

This will

assist in supply allocation and physician decisions when treating liver diseases.
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1.1 Bile acids (BA) synthesis, metabolism, and enterohepatic recirculation

Bile Acids (BA) are synthesized in the liver and excreted into bile, which flows to
the small intestine through the bile duct [1].

BA synthesis takes place in liver cells

through cytochrome P450-mediated oxidation of cholesterol in many steps [2]. The
major pathway of BA synthesis is initiated by hydroxylation of cholesterol at the 7α
position through the action of the CYPA1 enzyme [3]. The next step of BA synthesis
is the oxidation of the 3β-OH and isomerization of the C5-C6 double bond by the
microsomal C27-3β-hydroxylated dehydrogenase (C27-3β-HSD).

The forming

intermediates are either involved in hydroxylation at the 12α position through the action
of the CYP8B1 enzyme or passed to the next step [4]. The intermediates with 12α
hydroxylation produce CA, while intermediates that are not involved in hydroxylation
produce CDCA and CA that belong to primary BA in humans.

The next step of BA

synthesis is the hydroxylation and oxidation of a carboxylic acid. This occurs at the
C27 position through the action of the CYP27A1 enzyme followed by the bile acid
coenzyme-A (BA-CoA) synthetase [5]. The side chain of these C27 intermediates is
decreased to C24 BA through β oxidation.

The final step of BA synthesis is involved

in amidation of the BA-CoA with glycine(G) or taurine (T) via amino acid N
acyltransferase (BAT) [5].
BA can also be synthesized by alternative pathways, which do not require the
enzyme CYP7A1 to initiate their synthesis [6].

The alternative pathways of BA

synthesis are initiated through the hydroxylation of cholesterol at side chains C24, C25,
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or C27 by the action of the CYP7B1 and CYP39A1 enzymes [7]. Compared with the
major pathway of BA synthesis, the alternative pathways produce more CDCA.

Also,

these pathways are linked to conditions with deficiency in CYP7A1 activity [7].
The enterohepatic recirculation of BA describes the cycle of BA absorbed from
the intestine into the liver and then re-secreted into bile [1]. BA are excreted from
liver into bile through efflux transporters, which include the bile salt export pump
(BSEP), multidrug resistance protein 3 (MDR3), and multidrug resistance-associated
protein 2 (MRP2) [8]. After meal ingestion, cholecystokinin secretion prompts the
gallbladder to contract and empty its contents into the duodenum [9, 10].
Most amidated BA in the small intestine are absorbed in the ileum through the
apical Na+-dependent bile salt transporter (ASBT) or organic anion-transporting
polypeptides (OATPs) [9, 11].

These two transporters have higher affinity on

amidated BA compared with unconjugated BA [12]. Therefore, unconjugated BA are
passively absorbed via the intestinal tract due to low affinity on transporters and their
unionized forms [9, 10]. Also, partial deamination occurs from the bacteria in the
small intestine, and unconjugated BA are passively absorbed [13].
Unabsorbed BA are transferred from the small intestine to the large intestine [1].
BA undergo bacterial transformation of deamidation and dehydroxylation in the large
intestine [1, 14].

Due to the dehydroxyaltion of primary BA at the 7α position,

secondary BA are produced via bacterial transformation, such as DCA and LCA [1,
14]. Absorbed BA are extracted by the liver through active or passive diffusion. The
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majority of BA are amidated in hepatocytes.
such as sulfation and hydroxylation [1].
absorbed in the intestines [1, 14].

Other metabolic pathways take place

BA are excreted in feces when they are not
Finally, the enterohepatic cycle is completed

when the newly synthesized and reabsorbed BA are re-excreted into bile.
1.2 BA structure, function, and toxicity
BA are amphipathic steroid molecules synthesized in the liver from cholesterol
[3]. Figure 1.1 indicates the chemical structure of the major BA, which includes cholic
acid (CA), muricholic acid (MCA), hyocholic acid (HCA), chenodeoxycholic acid
(CDCA), deoxycholic acid (DCA), ursodeoxycholic acid (UDCA), murideoxycholic acid
(MDCA), hyodeoxycholic acid (HDCA), lithocholic acid (LCA), their glycine (G) and
taurine (T) amidates, and sulfate conjugates. Based on their chemical structure, BA
can be sorted into mono-OH BA (LCA), di-OH (MDCA, UDCA, HDCA, CDCA, and
DCA), and tri-OH (CA, HCA, and MCA).
The physiological functions of BA include cholesterol absorption and elimination,
fat absorption, and maintenance of a healthy microbiome [15].

Moreover, the

absorption of lipids and fat-soluble vitamins by emulsification is also related to BA's
physiological functions [16].

BA work as signalizing molecules by binding to

numerous receptors, especially the surface G-protein-coupled membrane receptor
(TGR5) and the nuclear farsenoid-X-receptor (FXR) [17].

Based on that, BA are

involved in regulating gene expression on cholesterol, glucose metabolism, and
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homeostasis.

For example, one type of primary BA, ursodexoxycholic acid (UDCA),

is associated with the treatment of cholestatic liver diseases[18].
BA also have cytotoxic and pathological effects at high concentrations.

BA

degrade cell membranes, have necrotic effects on mitochondria, detergent effects on
biological membranes and promote cell mutations that produce cancer [19-21]. In
more detail, BA bind to the lipid bilayer and increase solubility of plasma membrane
components at high concentrations.

At the intracellular level, BA decrease the

mitochondria integrity, and lead to the influence of permeabilization of mitochondria
membranes, such as depolarization of the organelle and mitochondrial swelling [22].
Based on that, BA cause mitochondrial collapse, release cytochrome c, and lead to
apoptosis.

Moreover, BA toxicity is associated with hydrophobicity [22].

The

increasing of BA hydrophobicity is linked to the efficiency of BA to solubilize membrane
lipids [22].

Therefore, BA toxicity increase when more hydrophobic BA are

synthesized.
1.3 Differences among individual BA
Individual BA are different from each other through to their physicochemical
properties, physiological, and pathological functions. One physicochemical property
is the lipophilicity of BA, which is determined by the side chain structures and BA
nucleus [23].

Amidation of BA side chain with G and T cause the reduction of

lipophilicity by decreasing pka, and it led to the increased solubility.

For example, the

acidity of unconjugated BA is associated with G and T amidation.

As amidation
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increases, pka is decreased from unamidated BA to G and T amidated BA [24]. The
number of hydroxyl groups (OH) on steroids nucleus shows an opposite relationship
with BA lipophilicity.

For example, tri-OH BA (CA and MCA) is less lipophilic than di-

OH BA (CDCA and DCA), which in turn is less lipophilic than mono-OH BA(LCA).
Moreover, the position and stereochemistry of OH groups are related to BA lipophilicity
[24]. For example, di-OH BA (UDCA) is less lipophilic than tri-OH BA (CA).

The

completed ionization of BA at physiological PH causes decreasing in lipophilicity and
increasing in solubility and leads to inactivation of membrane permeability.
BA are amphipathic molecules, and their anions self-associate to form micelles
in water.

The critical micelles concentration (CMC) is one of the important parameters

for BA cytotoxicity. It shows the propensity of molecules to dissociate or aggregate
in solutions and their level of

toxicity [25].

CA has higher critical micellar

concentrations than DCA and CDCA; therefore, it has less cytotoxicity at a given
concentration [26].

Moreover, BA hydrophobicity is another critical parameter to

determine BA toxicity. BA are planar molecules with two “faces”.

The one face does

not have OH groups, making it hydrophobic. The other face has OH groups, making
it hydrophilic.

Based on this, BA hydrophobicity also depends on the number,

position and orientation of OH groups.

The hydrophobic index (HI) is used to describe

the balance of hydrophilic and hydrophobic of individual BA.

HI of BA is calculated

from the retention time and capacity factor on a C18 column [1]. The range of HI is
from -0.94 for the hydrophilic BA (T-UDCA) to +1.46 for the hydrophobic BA(LCA).
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The hydrophobicity of individual BA is linked to membrane damage [26]. The lower
value of HI, the higher concentration of hydrophilic BA indicate the lower cytotoxicity
of BA [27]. Therefore, the individual BA such as DCA, CA, and UDCA can be ranked
based on their cytotoxicity, [26].
Affinity to various BA receptors can be influenced by the structural differences of
Individual BA.

The G protein-coupled receptor (TGR5) works as a cell-surface

receptor responding to BA [28]. For instance, primary BA (CDCA and CA) are less
potent TGR5 activators than secondary BA (LCA and DCA) [28].

Farnesoid X

receptor( FXR) is one type of nuclear receptor of transcription factors that regulates
BA metabolism [29, 30]. For example, primary BA such as CDCA is limited by FXR
activation, while secondary BA such as DCA is not [31]. However, glycine-β-MCA
(Gly-MCA) works as a FXR inhibitor in the intestine [30].
Individual BA are also differentiated by their pathological effects. For instance,
hydrophobic BA such as LCA cause cholestasis in rats and mice.

However,

hydrophilic BA such as CA cause hypercholeresis [32]. CA is also less likely than
LCA to cause red blood cell hemolysis [32]. T-amidates are less cytotoxic than Gamidates and cause less cell membrane lysis than the corresponding G-amidates [32,
33]. The amount and composition of the BA pool must be maintained to keep normal
physiological levels. This also prevents toxicity from the accumulation of toxic BA.
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1.4 Species Differences of BA
Major species differences in BA metabolism have been reported in previous
studies [34-38]. The detoxification of BA mainly focuses on several pathways, such
as conjugation (sulfation or glucuronidation), amidation (glycine or taurine), and
hydroxylation by CYP3A [1].

Glycine amidation is less likely to increase BA

hydrophilicity and decrease their toxicity than taurine amidation. Glycine amidation is
mainly observed in humans[39, 40], rabbits[41], and minipigs[42], while taurine
amidation is mainly observed in mice [6], rats [43], and dogs [44]. Hydroxylation at
the 6-α,6-β, and 7-β positions, which is the major pathway to produce hydrophilic toxic
BA, including MCA (mice), HCA (pigs) and UDCA(bears) [27]. BA sulfation are more
observed in humans and chimpanzees, and less observed in rabbits, rats and mice [6].
BA glucuronidation are a minor pathway in numerous species such as rats,
chimpanzees, mice and humans, while dogs show a high level of glucuronidation [45].
Major species differences are also reported in BA transport [17, 30, 32]. The
contribution of efflux through multidrug resistance–associated protein (MRP)
transporters to drug induced-toxicity are 5-fold lower in humans than rats [34]. The
affinity of MRP3 transporters in humans is relativity less than in rodents [55]. Similarly,
the uptake affinity of BA via NTCP (sodium-taurocholate co-transporting polypeptide)
and OATP (organic anion-transporting polypeptide) transporters is higher in rats than
in humans [35].
rodents[36].

Also, OATP1 and OAPT3 are not effective in humans, dogs or
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Moreover, major species differences in BA-induced toxicity have been reported
in previous studies and explained by species difference in BA metabolism [34-38].
CDCA cause harmful hepatic toxicity in monkeys [46], rabbits [47] and dogs [48]
because they lack BA sulfation capabilities.

Sulfation is the major pathway of BA

metabolism in humans and chimpanzees, therefore CDCA therapy is not linked to
hepatic injury for these species [46, 49-52]. Also, LCA and DCA are both hepatotoxic
in rabbits because of the lack of BA sulfation and hydroxylation [41, 47, 53]. Humans
are less resistant to CDCA, LCA than mice [54] and rats [55] because of their BA are
less hydrophilic due to hydroxylation and taurine amidation.

Therefore, species

difference to BA toxicity is mainly determined by their capability to efficiently metabolize
BA.
There are some limitations when using animal models for studying BA toxicity in
their metabolism.

BA sulfation has been considered as a primary detoxification

mechanism [1]. Amidation of BA with glycine and taurine amino acids enhance their
solubility and decrease their toxicity [56]. The sulfation of BA is highest in humans
and chimpanzees, while other species are very low across all BA in a vivo and in vitro
study. Also, the amidation of BA is highest in humans and lowest in rats in the same
study [45].

BA sulfation and amidation are important to understand the balance

between physiological and pathological effects [39]. For example, the inhibition of BA
sulfation and amidation decrease transporter-medicated vectorial transport and effect
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the liver’s ability for drug-induced adaptation [57]. Based on these limitations, using
animal models are not as useful as human models for studying BA toxicity.

1.5 BA and Hepatobiliary diseases
Cholestatic liver diseases are a diverse group of hepatobiliary diseases [2]. The
major cholestatic liver diseases include primary biliary cirrhosis (PBC) and primary
sclerosing cholangitis (PSC) [58].

Patients with PSC are most likely to develop

cirrhosis and end-stage liver disease [58].

Around 90 percent of patients with

compensated cirrhosis develop into ascites [59]. In liver disease severity, there are
decompensated and compensated liver diseases.

Patients with decompensated liver

diseases have severe complications, including liver damage and severe to the point
where the liver can no longer function.

These complications include ascites [59],

bacterial peritonitis [60], encephalopathy [61], GI bleeding [62], hepatobiliary
carcinoma [63], hepatorenal syndrome [64], jaundice [65], peripheral edema [66], and
portal hypertension [67]. Patients with compensated liver disease do not have severe
complications, which means the liver is scarred, but it can still perform most basic
functions [68].
BA have deleterious effects on the liver which includes cholestasis, changes in
liver structure, and hepatocyte ultrastructure [1, 69]. Cholestatic liver diseases are
associated with bile flow reduction, which is caused by the impairment of bile flow into
bile duct or defects in bile production [2].

Cholestatic liver diseases cause BA
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accumulation in the liver, spread into the circular system, extrahepatic tissues, and
urine.

Many research studies report the changing of BA concentrations in the blood

and urine at liver disease conditions [1, 70-72].
There are several human and animal studies illustrating the link between the
accumulation of toxic BA in the liver, blood and extrahepatic tissues, and unfavorable
liver disease prognosis [2, 39, 73, 74].

The accumulation of toxic BA in cholestasis

leads to hepatoxicity and extrahepatic toxicity [75].

For instance, BA concentrations

correlate to liver and bile duct damages in diseased rabbits, rats and humans [73, 7678].

Also, patients with high concentrations of BA are more likely to have

hepatobiliary complications after liver transplantation[73].

The intracellular

accumulation of toxic BA influences the upregulation of proteins connected with
hepatic bile secretion due to the imbalance of BA receptors such as FXR. After that,
it inhibits the hepatocellular uptake of BA and BA synthesis [74]. Moreover, toxic
individual BA are more associated with the damage inflicted on hepatocytes and
cholangiocytes than total levels of BA [2]. Therefore, the evidence from animal and
human studies supports the causal link between the accumulation of toxic BA and
unfavorable prognosis of hepatobiliary diseases.
1.6 BA as biomarkers of liver diseases

In the US, ten percent of people diagnosed with cholestatic liver diseases led to
end up with liver transplantation (LT) [79]. Even though liver transplantation is a wellknown therapy for patients with cholesteric liver diseases, one of the major challenges
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is a larger portion of the overall complications occur after LT [80]. For example, PBC
and PSC relapse after liver LT, and affect graft outcomes during a long period.
Moreover, Immunosuppression in LT with cholesteric liver disease is poorly
understand because of the increased acute cellular rejection in patients with
cholesteric liver diseases [79]. There are not enough data indicating a relationship
between a immunosuppression regimen and the risk of relapsing for liver cholesteric
liver diseases after patients undergo LT [79].
Aspartate

transaminase

(AST),

alanine

transaminase

(ALT),

alkaline

phosphatase (ALP), glutamyl transferase (GGT), serum creatinine, protime,
international normalized ratio (INR) are most commonly used as individual biomarkers
for the prognosis of hepatobiliary diseases (Table1.1). However, these biomarkers
are not specific to bile duct injuries or the liver, and may more commonly be associated
with non-hepatobiliary conditions [81]. For example, elevated level of serum ALT is
linked to toxicity in other organs besides the liver. Using these biomarkers can lead
to an under evaluation of the severity of the problem [82]. For example, ALT works
as a poor indicator of disease severity for hepatobiliary diseases such as cholestasis
[83].

In evaluating liver diseases, models with multiple parameters are preferred and

show high accuracy compared with models using an individual parameter, such as the
Child-Turcotte-Pugh (CTP) and the Mayo model for end-stage liver disease (MELD)
score.
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Many models, scores and criteria have been developed to predict the prognosis
of hepatobiliary diseases (Table1.2). The CTP score, originally used to determine
the risk of shunt surgery for liver disease severity [84]. The CTP score use three
biological variables (serum albumin, serum bilirubin and prothrombin) and two clinical
variables (ascites and encephalopathy).
the CTP score.

However, there are several limitations for

Variables of ascites and encephalopathy are easily affected by

extraneous factors [85]. Also, variables of bilirubin and creatinine make the end of
the CTP scale inaccurate [86].
Another model for liver diseases is the Mayo model for end-stage liver disease
(MELD). It is used to determine a patient's eligibility for liver transplantation in many
countries [87]. MELD uses three parameters which are serum bilirubin, International
normalized ratio (INR), and creatinine.

The MELD score contains a metric using a

continuous scale to predict the ranking of patients by disease severity [85]. These
three variables are reproducible and easy to measure.

Combined together, they give

a high accuracy on how the liver is functioning than CTP. The level of creatinine is
related to kidney function.

The level of bilirubin shows how well the liver clears bile.

INR reflects how well the liver makes factors needed for blood clots [85, 86]. When
MELD was implemented, it decreased post-transplant mortality rates.

MELD also led

to accurate predictions of surgical outcomes with alcoholic hepatitis and cirrhosis
patients [88].
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Even though it is used globally, MELD still has several limitations.

MELD

calculation is based on three variables that are not specific to all hepatobiliary diseases
[87]. For example, patients with a high level of serum creatinine are likely to have
kidney disease.

The changing status of serum bilirubin is linked to other conditions

like hemolysis or sepsis [89]. Moreover, in several studies, patients with a low MELD
score represent a high mortality rate and a less accurate MELD score [89, 90]. Based
on these issues, using the MELD score to estimate liver disease severity needs to be
reconsidered.
Further diagnosis and prognosis of liver disease is critical and depends on
invasive procedures, endoscopic treatment and evaluation of liver biopsies [91].
Based on these, noninvasive biomarkers are needed to help on prognosis, diagnosis,
and evaluation.

For several decades, BA has been considered as potential

biomarkers for many hepatobiliary diseases based on their accumulation and
hepatoxicity in hepatobiliary diseases [1]. For example, PSC [92], PBC [92], alcoholic
liver disease [92], nonalcoholic fatty liver disease [93], hepatitis intrahepatic cholestatic
of pregnancy [94].

BA biomarkers are an accurate, noninvasive option that can

improve the diagnosis and prognosis of liver diseases [95-97].

Not only are they

being more accurate, but they are also a vital addition to treatment and evaluation of
hepatobiliary diseases.
diseases.

They could improve the therapeutic outcomes for these
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1.7 BA indices
Even though BA as biomarkers have been extensively used for hepatobiliary
diseases, they have not been effectivity used in clinical studies due to several
limitations.

Individual BA concentrations are better correlated to the hepatobiliary

liver condition than total BA concentrations due to the difference in the various BA's
physiological and pathological properties [26, 72]. Moreover, total and individual BA
concentrations reflect high inter- and intra-individual variability and make it hard to
identify baseline ranges in the absence of liver diseases.

BA have shown high inter-

individual variability based on several factors, including gender, alcohol consumption,
and obesity [97-100]. Also, serum and urinary BA levels show high intra-individual
variability due to many factors, such as medication intake, and food ingestion [71, 101103].
Based on these limitations, we have investigated the concept of "BA indices",
which are ratios calculated from the absolute individual BA concentration and their
metabolites [39]. These ratios are used to characterize BA profiles by quantifying BA
composition, hydrophilicity, toxicity, formation of secondary BA, and metabolism [2, 39,
104, 105]. BA indices have numerous benefits compared to total and individual BA
concentrations.

BA indices have low inter- and intra-individual variability.

For total

and individual absolute BA concentrations in urine, the relative standard deviation
(RSD) is from 66% to 256%, but it is from 10% to100% for BA indices in the same
population of health subjects [39].

Serum BA level increases after food ingestion
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because of cholecystokinin's release, which leads to gallbladder contraction resulting
in increasing bile flow into intestine [39].

Therefore, feeding status has to be

controlled before the use of serum BA as a reliable biomarker.

Moreover, the

absolute and most individual BA concentrations increase more than 2-fold one hour
after a standard meal. However, BA indices only change 10% in the same individual
BA after a standard meal [39]. Also, the same trend has shown in urine, urinary BA
indices have smaller inter-and intra-variability than in serum.

For instance, the

percentage of RSD of overall BA was 8% and 47% in urine and serum [39]. Moreover,
urinary BA indices are resistant to feeding status compared with absolute BA
concentrations in the same population [39].

Therefore, noninvasive urinary BA

indices are significantly better than absolute urine or serum BA concentrations for
treating hepatobiliary diseases.

In addition, urinary BA indices have better

performance than serum liver enzymes such as ALT and AST or total BA
concentrations in humans and in animal models for cholestatic liver disease diagnosis
and prognosis [2].
1.8 Research objectives
In this study, we have extended the application of BA indices to predict liver
disease prognosis by recruiting 257 patients with liver diseases over a period of seven
years.

The study focuses on developing prognostic models based on BA indices to

predict the individual complication in the entire liver-patient population. In other words,
it is used for indicating the prognosis of the complication from a grouped population of
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liver disease subtypes, with an emphasis on the relationship between the BA indices
and the severity of the complication. The various BA, non-BA, and MELD models
were compared for their accuracy in predicting the prognosis of liver diseases via
statistical tests.
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CHAPTER 2

URINARY BILE ACID INDICES AS PROGNOSTIC BIOMARKERS
FOR ASCITES ASSOCIATED WITH LIVER DISEASES
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2.1 Introduction
Cholestatic liver diseases is a diverse group of hepatobiliary diseases associated
with limitations in bile flow due to a failure of bile flow or an impairment in bile
production [2]. Relatively common cholestatic liver diseases include primary biliary
cirrhosis (PBC) [58], primary sclerosing cholangitis(PSC) [58], alcoholic liver disease
[106], and nonalcoholic fatty liver disease [93].
Common complications associated with cholestatic liver diseases include ascites
[59], bacterial peritonitis [60], encephalopathy [61], GI bleeding [62], hepatobiliary
carcinoma [63], hepatorenal syndrome [64], jaundice [65], peripheral edema [66], and
portal hypertension [67].

In particular, ascites is one of the most common

complications associated with cirrhosis.

The risk of developing ascites is around 60%

if the cause of cirrhosis has not been treated [107]. Cirrhosis is an advanced-stage
liver disease caused by fibrosis, which impedes the intrahepatic blood flow, increases
portal blood pressure, and causes accumulation of fluids in the peritoneal cavity
(ascites) [108]. The survival of cirrhosis patients decreases from 80% to 50% when
these patients are diagnosed with ascites [109].

Cirrhosis patients with ascites

experience several symptoms, such as nausea [110], abdominal distention [111],
dyspnea [112], edema [113], and hepatorenal syndrome [114].
Aspartate

transaminase

(AST),

alanine

transaminase

(ALT),

alkaline

phosphatase (ALP), glutamyl transferase (GGT), serum creatinine, protime, and INR
(international normalized ratio) are commonly used biomarkers for the diagnosis and
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prognosis of liver diseases [81-83]. However, these biomarkers are not specific to
bile duct or liver injuries, and may be related to non-hepatobiliary conditions [81].
Therefore, models with multiple parameters/markers were developed to better predict
the prognosis of liver diseases with higher accuracy than individual parameters [84,
86].
Models with multiple parameters have been used globally to predict survival of
hepatobiliary disease-related complications such as the Child-Turcotte-Pugh (CTP)
and the Mayo model for end-stage liver disease (MELD) scores [85, 109].

The CTP

score was originally used to determine the risk of shunt surgery for severity of liver
disease and its complications, such as GI bleeding and encephalopathy [115, 116].
The MELD score was originally used to estimate survival of liver patients undergoing
the transjugular intrahepatic portosystemic shunt (TIPS) [85]. The MELD score is
currently used to determine a patient's eligibility for liver transplantation [87].

In

addition, the MELD score is used as a good predictor of outcome in liver disease
complications, such as GI bleeding and portal hypertension [85, 115]. Even though
the CTP and MELD scores have been used globally, they still have several limitations.
Variables of ascites and encephalopathy are easily affected by extraneous factors in
the CTP score [85]. And the MELD score has a poor evaluation for patients with
cholestatic liver disease-related complications, such as ascites and encephalopathy
[86].
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More recently, bile acids (BA) have been considered as potential biomarkers for
prognosis of hepatobiliary diseases [117, 118]. BA are synthesized in the liver and
excreted into bile, which then flows to the small intestine via the bile duct [8]. BA have
many physiological functions, such as fat absorption and cholesterol elimination [15,
17]. Compared to their physiological functions, BA also exhibit pathological effects at
high BA concentrations. They are associated with necrotic effects on mitochondria,
detergent effects on biological membranes, and cancer promoting effects [20, 21].
There are a plethora of human and animal studies illustrating the link between the
accumulation of toxic BA in the liver, blood and extrahepatic tissues, and unfavorable
liver disease prognosis [2, 39, 73, 74].
However, BA have not been widely used in the clinic as biomarkers for liver
diseases due to several limitations.

Individual BA concentrations are better

correlated to hepatobiliary diseases than total BA concentrations due to the difference
in the various BA's physiological and pathological properties [26, 72]. Both individual
and total BA concentrations have high inter-and intra-variability under normal
conditions due to several factors including weight, gender, and alcohol consumption,
food ingestion, diurnal variation, and medication intake.

Therefore, the normal

baseline ranges are difficult to establish [71, 97-103].
To address these limitations, we have established the concept of “BA Indices.”
BA indices are ratios calculated from the absolute individual BA concentration and their
metabolites [2, 39, 104, 105]. BA indices have markedly low inter-and intra-individual
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variability and are more resistant to the above-mentioned cofactors than absolute BA
concentrations.

For example, the absolute total and individual BA concentrations

increased more than 2-fold in individuals one hour after a standardized meal, while BA
indices changed less than 10% in the same individuals [39]. Furthermore, we have
demonstrated that urinary BA indices outperformed the currently used blood liver
enzymes as biomarkers for cholestatic liver diseases [2, 39]. In addition, we have
recently developed a BA-based survival model (the BA score (BAS) model) to predict
the prognosis of cholestatic liver diseases [119]. BAS had a higher true-positive and
true-negative prediction of 5- and 3-year death and liver transplant than other non-BA
models including MELD.
Multiple markers and models are used to predict the survival of cholestatic liver
diseases [120, 121]. However, very few studies have addressed the prognosis of
cholestatic liver disease-related complications.

For example, the CTP score has

widely been used in the prognosis of cirrhosis, but it does not provide clear guidance
of prognosis for cirrhotic patients with complications [122]. Similarly, the MELD score
has extensively been used to prioritize cirrhotic patients awaiting liver transplantation
[123], but it still does not correlate with cirrhosis-related complications, including
encephalopathy and bacterial peritonitis [124]. Therefore, there is a critical need for
markers/models to particularly predict complications of liver diseases.
In this study, we have expanded the application of BA indices to predict
complications, especially ascites, in patients with liver diseases. The study focuses
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on developing prognostic models based on BA indices to predict the development of
ascites in liver patients.
2.2 Materials and methods

2.2.1 Study participants

Patients with hepatobiliary conditions were diagnosed by University of Nebraska
Medical Center’s (UNMC) hepatology Clinic (Omaha, NE, USA).

The institutional

review board (IRB) approved this study at UNMC. Hepatobiliary conditions included
Chronic Hepatitis C, Chronic hepatitis B, Alcoholic Liver disease, Primary biliary
cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Autoimmune Hepatitis,
Alpha-1-antitrypsin deficiency, Nonalcoholic Fatty Liver Disease, Nonalcoholic
Steatohepatitis (NASH), Cryptogenic Cirrhosis and Nonalcoholic Steatohepatitis.
The following complications were diagnosed and monitored by the hepatologists:
Hepatobiliary Carcinoma, Gastrointestinal Bleeding, Portal Hypertension, Ascites,
Peripheral edema, Encephalopathy, Jaundice, Bacterial Peritonitis, Hepatorenal
Syndrome.

Two-hundred fifty-seven patients with cholestatic liver diseases between

the ages of 19 and 65 years (121 female and 136 male) were treated at the UNMC
from November of 2011 to December of 2018 were recruited into the study.

Thirty

milliliters' urine samples were collected from patients on every visit to the hepatology
Clinic.

All urine samples were stored at -80℃ before BA analysis using liquid

chromatography-tandem mass spectrometry (LC-MS/MS) until analyzed.
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2.2.2 Non-BA parameters

The performance of potential biomarkers from the urinary BA profile has also
been compared with the performance of existing markers of liver function including
alanine transaminase (ALT), aspartate transaminase (AST), serum creatinine,
albumin, bilirubin, international normalized ratio (INR), protime, AST/ ALT ratio, and
AST/ platelet ratio index (APRI).

2.2.3 Bile acid (BA) quantification by liquid chromatography-tandem mass
spectrometry (LC-MS/MS)

BA concentrations were quantified by LC-MS/MS, as described previously [2, 6,
39, 40, 104]. Briefly, a Waters ACQUITY ultra performance liquid chromatography
(UPLC) system (Waters, Milford, MA, USA) coupled to an Applied Biosystem 4000 Q
TRAP® quadrupole linear ion trap hybrid mass spectrometer with an electrospray
ionization (ESI) source (Applied Biosystems, MDS Sciex, Foster City, CA, USA) was
used to perform the LC-MS/MS analysis.

All chromatographic separations were

performed with an ACQUITY UPLC® BEH C18 column (2.1x 150 mm, 1.7 μm)
equipped with an ACQUITY UPLC C18 guard column (Waters, Milford, MA, USA).
The following MS source settings were used: temperature, 500°C; ion spray voltage,
−4000 V; collision gas pressure, high; curtain gas, 20; gas‐1, 35; gas‐2 35 (arbitrary
units); Q1/Q3 resolution, unit; and interface heater, on.

Mobile phase consisted of

7.5 mM ammonium bicarbonate, have been adjusted to pH 9.0 by using ammonium
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hydroxide (mobile phase A) and 30% acetonitrile in methanol (mobile phase B) at a
total flow rate of 0.2 ml/min.

The gradient profile was held at 52.5% mobile phase B

for 12.75 minutes, increased linearly to 68% in 0.25 minutes, held at 68% for 8.75
minutes, increased linearly to 90% in 0.25 minutes, held at 90% for one minute and
finally brought back to 52.5% in 0.25 minutes and then followed by 4.75 minutes re‐
equilibration (total run time of 28 minutes per sample).

2.2.4 Preparation of standard solutions and calibration curves

For the preparation of standard solutions and calibration curves, blank matrices
were obtained by charcoal stripping as mentioned early [2, 6, 39, 104].

Stock

solutions of individual unsulfated BA and the IS (2H4-G-CDCA) were prepared in
methanol (MeOH) at a concentration of 10 mg/mL and stock solutions of individual
sulfated BA were prepared in deionized water at a concentration of 1 mg/mL. Human
urine was incubated with 100 mg/mL activated charcoal for two hours to remove
endogenous BA from the matrix. The mixture was then centrifuged at 16000 x g for
10 min, and the supernatant was aspirated and filtered using a 0.22-μm nylon filter.
The filtrate from the stripped urine matrix was used for preparing the calibration curve.
Eleven‐point calibration curve was prepared by spiking 10 μL of the appropriate
standard solutions and 10 μL of the IS stock (2H4-G-CDCA) into 100 μL of the stripped
urine matrices. The final concentration of IS was 500 ng/ml and the dynamic range
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of the standard curves for the various unsulfated and sulfated BA analytes was 1-1000
ng/ml.

2.2.5 Sample preparation

Solid phase extraction was used to extract urine samples as mentioned previously
[2, 6, 39, 40, 104].

100 μL of urine samples were spiked with 10 μL of internal

standard (IS), vortexed and loaded on to SupelcleanTM LC‐18 SPE cartridges preconditioned with 4 mL MeOH, followed by 4 mL H2O. Loaded cartridges were then
washed with 3 mL H2O and eluted with 4 mL MeOH. The eluates were evaporated
under vacuum at room temperature and reconstituted in a 100 μL of 50 % MeOH
solution.

Ten microliters of reconstituted samples were injected for LC-MS/MS

analysis.

2.2.6 Calculation of BA indices

The BA profile in urine was characterized using BA “indices”, as we have
described previously [2, 39, 40, 45, 104]. Table 2.1 shows a summary of the BA
indices used in the current study.

BA indices describe the composition, hydrophilicity,

formation of 12α-OH BA by CYP8B1, metabolism, and formation of secondary BA by
intestinal bacteria.

The composition indices were calculated as the ratio of the

concentration of individual BA in all their forms (unamidated, amidated, unsulfated and
sulfated) to the total concentration of BA.

Hydrophilicity indices include the
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percentages of the BA pool exist as mono-, di-, or tri-OH BA as well as the
hydrophobicity index (HI) of the BA pool.

The percentages of mono‐OH BA (LCA),

di‐OH BA (UDCA, MDCA, HDCA, DCA and CDCA) and tri‐OH BA (CA, MCA, and HCA)
were calculated as the ratio of the concentration of the sum of the respective BA in all
their forms to the total concentration of BA.

HI was calculated according to the

Heuman index, which based on the relative contributions of the individual BA to the
total BA pool and their HIs [125].
12α-OH BA are formed by CYP8B1 in the liver and include DCA, CA, Nor-DCA,
and 3-dehydroCA.

Therefore, CYP8B1 activity can be measured by the ratio of 12α-

OH BA to the remaining of all other BA (non-12α-OH BA).

Another marker for

CYP8B1 is the ratio of CA to CDCA because CA is formed by the 12α hydroxylation of
CDCA.

In the same way, the ratio of 12α‐OH (DCA, CA, Nor-DCA, and 3-dehydroCA

in all their forms) to non‐12α‐OH (HDCA, CDCA, UDCA, LCA, MDCA, MCA, HCA, 12oxo-CDCA, 6-oxo- LCA, 7-oxo-LCA, 12-oxo-LCA, isoLCA, isoDCA in all their forms)
was calculated.
BA are primarily metabolized by sulfation, and glycine (G), and taurine (T)
amidation in the liver.

The percentage of sulfation of individual BA was calculated as

the ratio of the concentration of sulfated BA, in both the unamidated and amidated
forms, to the total concentration of individual BA in all their forms (unamidated,
amidated, unsulfated, and sulfated).

The percentage of amidation of individual BA

was calculated as the ratio of the concentration of amidated BA, in both the unsulfated
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and sulfated forms, to the total concentration of individual BA in all their forms
(unamidated, amidated, unsulfated, and sulfated).

In addition, percentages of

amidation were divided into the percentages of BA existing as taurine (T) or as glycine
(G) amidates.
Primary BA are synthesized in the liver and secreted into the intestine via bile,
where they are metabolized by intestinal bacteria into secondary BA.

The ratio of

primary (CA, CDCA, MCA and HCA in all their forms) to secondary BA (DCA, LCA,
UDCA, HDCA, MDCA, Nor-DCA, 12-oxo-CDCA, 3-dehydroCA, 6-oxo-LCA, 7-oxo-LCA,
12-oxo- LCA, isoLCA, and isoDCA in all their forms) was also calculated.

2.2.7 Model development

Logistic regression analysis was used to develop prognostic models to predict
the prognosis of hepatobiliary diseases in terms of developing disease-related
complications. Models were constructed to predict (i) various individual complications
and (ii) all complications combined (pooled) in the entire liver-patient population as well
as in the individual disease subtype-populations (patient groups with specific disease
subtypes).

All statistical analysis was conducted using the Statistical Product and

Service Solutions (SPSS) software, version 26 (IBM corporation, Armonk, NY, USA).
We developed models that can be classified into six categories: (i) BA variables
only, (ii) Non-BA variables only, (iii) Mixed BA and non-BA variables, (iv) Original Model
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for end-stage liver disease (MELD), (v) MELD variable with coefficients from our data
set, and (vi) Original MELD modified with BA and/or non-BA variables.
Individual BA and/or non-BA variables were analyzed as possible predictors in a
univariate logistic regression analysis.

Significant variables (P<0.05) were selected

from the univariate analysis to include in the multivariate analysis.

The backward

elimination regression method was used to retain the most significant variables with
retention criteria of P < 0.05 during the multivariate analysis.
The estimated odds ratio (OR) of developing complications by BA and/or nonBA variables was calculated from the final multivariate logistic regression model for all
subjects.
log (OR) = log [

̂
P
] = a + b1 x1 + ⋯ + bk xk
̂
1−P

Where ̂
P is the probability of developing complications; a is the intercept; and b
represents regression coefficients for the x variables [126].
The final multivariate logistic regression model describes the association
between significant BA and/or non-BA variables and the odds of developing
complications.

Then, we rewrote the multivariate logistic regression model as a

function of the predicted probability, which transforms the estimated probabilities of
complications to a scale of 0 to 1 using the following equation:

̂
P=

exp( log (OR))
1 + exp( log (OR))
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2.2.8 Model goodness of fit, validation and performance

Goodness of fit was assessed by using the Hosmer–Lemeshow test for logistic
regression models.

This test compares the observed number of individuals to the

expected number of individuals in each pattern, which shows how well the data fits into
the model [126]. In general, the Hosmer–Lemeshow test indicates a poor fit if the
value is less than 0.05.
We used Akaike information criterion (AIC) to estimate out-of-sample prediction
error from multivariate logistic regression models [127].

AIC values were derived

from the likelihood function of models and result in a maximum likelihood estimate in
the same data set [127]. Therefore, AIC values were used to compare models with
different error distribution.

Minimizing AIC values represents a good trade-off

between goodness of fit and degrees of freedom [128].

The AIC values were

calculated by:
𝐴𝐼𝐶 = −2 ln(𝐿) + 2𝐾
Where 𝐿 is the maximized likelihood function; 𝐾 is the number of parameters
in the different models [129].
Bootstrapping was used to validate the models. Bootstrapping is a resampling
technique used to estimate statistics on a population by sampling a dataset with
replacements [130].
[131].

The parameters included P-value, Bias, and Standard Error

The bootstrapping estimate of bias indicated the difference between the

estimates computed using the original sample and the mean of the bootstrap estimate.
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The standard error represented the standard deviation of the estimator and reflects
how far our sample estimate deviates from the actual parameters [132]. The range
of regression coefficients (B) was defined as the 95% confidence interval of the
bootstrap estimator.

Acceptance criteria of P-values were set at 0.05.

We also performed receiver operating characteristic curve (ROC) on the scores
from multivariate logistic regression models to determine their cut-off value in
differentiating patients with or without ascites.

The cut-off values with optimum

specificity vs. sensitivity were selected and the areas under the ROC curve (AUC)
values were calculated. AUC of 0.9 or greater is rarely seen, AUC between 0.8 and
0.9 indicates excellent diagnostic accuracy, and any AUC over 0.7 may be considered
clinically useful [126].
The performance of the different models in predicting the occurrence of
complications were compared using statistical outcomes from the Hosmer–Lemeshow
test, AIC values, bootstrapping, and AUC values.

2.3 Results

2.3.1 Demographics

Table 2.2 shows a summary of patients who participated in this study. The
demographic variables included age, BMI, gender, and race.

During the 7-year

follow-up period, there were 257 patients with cholestatic liver diseases. The
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development of the following liver disease-related complications was monitored:
ascites (62), bacterial peritonitis (2), encephalopathy (36), GI bleeding (18),
hepatobiliary carcinoma (15), hepatorenal syndrome (1), jaundice (7), peripheral
edema (63), and portal hypertension (106).

2.3.2 Univariate logistic regression analysis for ascites prediction in the entire
liver-patient population

Table 2.3 shows the results of univariate logistic regression analyses for ascites
prediction by BA indices in the entire liver-patient population. The odds ratio (OR)
quantifies the magnitude of the risk of developing ascites per one unit as well as 10%
and 20% change of the normal value changes in BA indices. We found correlation
between the odds of developing ascites and many BA indices (P < 0.05).

Positive

regression coefficients (B) values indicate that odds of developing ascites increase
with increasing the values of BA indices, while negative coefficients imply the odds of
developing ascites increase with decreasing the value of BA indices.

For example,

for every 20% increase in the % CDCA, the odds of developing ascites increased
1.387-fold (OR: 1.387; P < 0.05).

In contrast for every 20 % increase in %MDCA, the

odds of developing ascites decreased 0.774-fold (OR: 0.774; P<0.05).
We performed the same univariate logistic regression analysis for demographics
and non-BA parameters as well (Table 2.4). For demographics, only gender was
significant (p < 0.05), with the odds of developing ascites being significantly 1.3-fold
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higher in males than females.

For non-BA parameters, increasing levels of creatinine,

INR, protime, AST, bilirubin, AST/ALT, and MELD significantly increased the odds of
developing ascites, whereas decreasing levels of albumin and ALT significantly
increased the odds of developing ascites. For every 20 % increase in the INR, the
odds of developing ascites increased 1.391-fold (OR: 1.391; P < 0.05). In contrast,
for every 20 % increase in the albumin, the odds of developing ascites decreased
0.231-fold (OR: 0.231; P < 0.05).

2.3.3 Multivariate logistic regression analysis for ascites prediction in the entire
liver-patient population

The BA Model
In multivariate logistic regression analysis, a backward elimination regression
was used to retain the most significant BA variables from univariate analysis.
The only BA variables retained in the multivariate model were %MDCA and %
Primary BA, which were independently predictive of developing ascites (Table 2.5.a).
The estimated odds ratio (OR) of developing ascites as a function of BA variables (BAOR) for individual patients were calculated using this equation:
BA score = Log (BA-OR) = -3.463-(2.452 ×% MDCA) + (0.045 ×% PrimaryBA)
̂) of ascites as a function of BA (BA-P
̂) variables is
The predicted probability (P
then calculated using this equation:
̂) =
BA (P

exp ( Log (BA OR))
1 + exp( Log (BA OR))
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̂) as predicted by
Figure 2.1.a shows the probability of developing ascites (BA-P
the BA score.
For example, for a patient with a %MDCA of 1%, and %Primary BA of 30%, the
estimated odds ratio (BA-OR) of developing ascites by BA variables:
BA score = Log (BA-OR) = -3.463-(2.452 ×1%) + (0.045 ×30%) = -4.564
̂) by BA variables can
Then, the predicted probability of developing ascites (BA-P
be calculated as:
̂) =
BA (P

exp ( − 4.565)
= 0.01
1 + exp( − 4.565)

We tested the effect of the significant demographic variables from univariate
analysis, i.e., gender, on this BA multivariate model.

Gender was retained in the

multivariate analysis but with no-minimal improvement of model validation criteria,
including the bootstrapping approach (Appendix. Table A). For example, %MDCA
and %Primary BA variables did not show any improvement for their p-values when
compared with the BA model without gender. The value of bias, standard error, and
relative standard error was not decreased in the BA model with gender. Furthermore,
gender was retained in the BA model with no-minimal improvement for model
comparison, including akaike information criterion and area under the ROC curve
(Appendix. Table B). For example, the AIC and AUC value was 215.63 and 0.833
which resulted in relatively minimal improvement to both values from the BA model
without gender (AIC:223.56; AUC:0.811).
the multivariate logistic regression model.

Therefore, we did not include gender in
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The Non-BA model
Albumin level and MELD were the only significant predictive variables of
developing ascites (Table 2.1.b).

The estimated odds ratio (OR) of developing

ascites as a function of non-BA variables (non-BA-OR) for individual patients was
calculated from this equation:
g

non − BA score = Log (non BA OR) = 0.947 − (1.205 × Albumin level (dl)) +
(0.189 × MELD)
̂) of developing ascites as a function of non-BA (nonThe predicted probability (P
̂) variables were calculated using this equation:
BA-P
̂) =
Non BA (P

exp( Log (non BA OR))
1 + exp( Log (non BA OR))

Figure 2.1.b shows the probability of developing ascites as predicted by the nonBA score.
For example, for a patient with albumin level of 1 g/dl, and MELD of 5, the
estimated odds ratio (non-BA-OR) of developing ascites by non-BA variables:

g

non − BA score = Log (non BA OR) = 0.947 − (1.205 × 1 (dl)) + (0.189 × 5 ) =
0.687
̂ ) of developing ascites by non-BA
Then, the predicted probability (non-BA- P
variables can be calculated as:
̂) =
Non BA (P

exp( 0.687)
= 0.67
1 + exp( 0.687)
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We performed the same multivariate logistic regression analysis for
demographics and non-BA parameters as well.

The results of the demographic

variable (gender) were the same as the BA model.

Because of no-minimal

improvement on model validation and comparison, we did not include it in the
multivariate logistic regression for the non-BA model (Appendix. Table A-B).

The Mixed BA and Non-BA model
The

variables

retained

in

the

multivariate

model

were

%CDCA,

primary/secondary BA, albumin level, and MELD which were independently predictive
of developing ascites (Table 2.5.c). The estimated odds ratio (OR) of developing
ascites by mixed BA and non-BA for individual patients was calculated from this
equation:
mixed BA and non − BA score = Log (mixed BA and non BA OR) = − 0.275
+ (0.029 × %CDCA) − (0.077 ×

PrimaryBA
)
SecondaryBA

g
− (1.143 × Albumin level ( )) + (0.189 × MELD)
dl
̂) of developing ascites as a function of mixed BA and
The predicted probability (P
̂) variables were calculated using this equation:
non-BA (mixed BA and non-BA-P
̂) =
Mixed BA and non BA (P

exp( Log (mixed BA and non BA OR))
1 + exp( Log (mixed BA and non BA OR))

Figure 2.1.c the probability of developing ascites as predicted by the mixed BA
and non-BA score.
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For instance, for a patient with %CDCA of 15%, Primary/Secondary BA of 1,
Albumin level of 1 g/dl, and MELD with 2, the estimated odds ratio (mixed BA and nonBA-OR) of developing ascites by mixed BA and non-BA variables:
mixed BA and non − BA score = Log (mixed BA and non BA OR) = − 0.275
g
+ (0.029 × 15) − (0.077 × 1) − (1.143 × 1 ( )) + (0.189 × 2)
dl
= −0.682
̂) of developing ascites by
Then, the predicted probability (mixed-BA and non-BA -P
mixed BA and non-BA variables can be calculated as:
exp( − 0.682)

̂) =
Mixed BA and non BA (P

= 0.34

1 + exp( − 0.682)
The demographic variable (gender) results for multivariate regression analysis
in this model were the same as the previous models (Appendix. Table A-B). Thus,
we did not include gender in the multivariate logistic regression for the mixed BA and
non-BA model.

The Original MELD model
We also performed the same multivariate logistic regression analysis for the
MELD parameter (Table 2.5.d). The estimated odds ratio (OR) of developing ascites
as a function of original MELD variables for individual patients was calculated from this
equation:
original MELD score = Log (MELD − OR) = − 4.049 + (0.276 × MELD)
̂) of developing ascites as a function of original MELD
The predicted probability (P
variables were calculated using this equation:
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̂) =
MELD (P

exp( Log (MELD))
1 + exp( Log (MELD))

Figure 2.1.d shows the probability of developing ascites as predicted by the
original MELD score.
For example, for a patient with MELD of 1, the estimated odds ratio (MELD) of
developing ascites by MELD variables:
original MELD score = Log (MELD − OR) = − 40.49 + (0.276 × 1) = −3.773
Then, the predicted probability (MELD- ̂
P ) of developing ascites by MELD
variables can be calculated as:
̂) =
MELD (P

exp( − 3.773)
= 0.02
1 + exp( − 3.773)

Similar to the BA model development, we did not include gender in this model
(Appendix. Table A-B).
Other Hybrid Models
In addition, we used the same methodology to develop other models (Appendix.
Table C) including: (i) MELD variables with coefficients from our data set to create a
model with the original MELD variables, but with model coefficients derived from our
data set. In this model, creatinine and INR variables from the original MELD were not
statistically significant. (ii) Original MELD modified with BA or non-BA variables at a
time, to test if the performance of the original MELD could be improved by adding
significant BA or non-BA parameters from the univariate analysis.

Original MELD

modified with BA variables only did not pass the Hosmer–Lemeshow test (P-value
<0.05), while original MELD modified with non-BA variables only did improve the
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performance of the original MELD variables.

However, this model has poor

performance because of the low AUC (0.865) and high AIC (171) values compared to
the mixed BA and non-BA model.

(iii) Original MELD was modified with both BA

and non-BA variables, to test if the performance of the original MELD could be
improved by adding both significant BA and non-BA parameters from the univariate
analysis. This model did not result in any improvement compared to the mixed BA
and non-BA model (Table 2.5.c). In this model’s performance, AUC (0.875) and AIC
(167) values were the same as the mixed BA and non-BA model. Since none of these
models has improved the performance of our main models, we did not further evaluate
any of these approaches.
Similar to the BA model development, gender was not included in other hybrid
models (Appendix. Table D).

2.3.4 Model goodness of fit, validation, and performance

The Hosmer–Lemeshow test was used as one criteria to evaluate goodness of
fit for all logistic regression models. For the BA model, the p-value of the Hosmer–
Lemeshow (HL) test was 0.168 (p>0.05), which means that the observed and expected
results were not significantly different, indicating the logistic regression of the BA model
fit the data well. Other models including the non-BA model (p=0.228), the mixed BA
and non-BA model (p-value = 0.11) also had a p value > 0.05. For the original MELD
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model, the p-value of the Hosmer–Lemeshow test was 0.029 (p< 0.05), indicating the
logistic regression of the original MELD model did not fit the data well (Table 2.6).
Table 2.6 also shows the Akaike information criterion (AIC) for ascites prediction.
AIC values were used to compare models with different error distribution.

The AIC

values for the BA, non-BA, mixed BA and non-BA, and original MELD models were
223.56, 170.81, 167.3, and 180.45. The BA model had a larger AIC value than the
non-BA, mixed BA and non-BA, and original MELD models, which means this model
did not have a good trade-off between goodness of fit and degrees of freedom. This
indicates that the logistic regression of the BA model demonstrated a large error
distribution.
Table 2.7 describes the bootstrapping validation for ascites prediction.
Bootstrapping validation results for all four models indicated that the regression
coefficients (B-value) were in the range of the 95% confidence intervals and p-values
were statistically significant for all covariates (p-value<0.05).

Bias values were

relatively small (-0.056 to 0.016), which means the estimates calculated using the
original sample and the mean of the bootstrap estimate were not significantly different.
In contrast, standard error (SE) and relative standard error (RSE) (0.02% to 296.3%)
values of the bootstrapping analysis were relatively high, which may reflect our sample
estimate derivates far from the actual parameter (Appendix. Figure A).
Figure 2.2 shows the receiver operating characteristics (ROC) curves of all four
models for ascites prediction.

The area under the ROC curve (AUC) for the BA, non-
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BA, mixed BA and non-BA, and original MELD were 0.81, 0.87, 0.88, and 0.86,
respectively.
We also calculated the sensitivity (SEN), specificity (SPE), positive predictive
value (PPV) and negative predicative values (NPV) from ROC analysis (Table 2.6).
For instance, in the BA model, the sensitivity and specificity were 33.90% and 88.30%,
the positive and negative predictive values were 48.80% and 80.20%.
Potential cut-off values of all 4 model scores to best differentiate patients with vs.
without ascites were selected based on the optimum sensitivity vs. specificity from
ROC analysis. The ROC-optimum cut-off values for BA, non-BA, mixed BA and nonBA models, and original MELD models for ascites prediction were -0.99, -1.18, -1.06,
and -1.09, respectively (Table 2.6).
Moreover, we tested if patient populations with scores below vs. higher than these
optimum cut-off values can be distinguished using ROC analysis. The p-value of
AUCs were used to find statistically significant differences between the low- vs. highscore populations (Figure 2.3 and Table 2.8). The null hypothesis for p-value of
AUCs were AUC=0.5.

2.3.5 Prediction for other complications

We also followed the same approach to predict other complications of liver
diseases including bacterial peritonitis, encephalopathy, GI bleeding, hepatobiliary
carcinoma, hepatorenal

syndrome, jaundice, peripheral

edema,

and

portal
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hypertension.

Appendix. Table E shows the ROC analyses, p-values of the

bootstrapping, Hosmer-Lemeshow tests, and Akaike information criterion (AIC) tests
for the BA models.

Appendix. Tables F-H show similar results for non-BA, mixed

BA and non-BA, and original MELD models.

2.4 Discussion

In this study, we have examined the ability of BA indices to predict complications
in patients with liver diseases.

Logistic regression analysis was used to develop

models to predict the prognosis of hepatobiliary diseases in terms of developing
disease-related complications. In addition to the BA model, we have developed (i)
non-BA, (ii) mixed BA and non-BA variables to compare with the BA-only and non-BA
only models. (iii) MELD variables with coefficients from our data set were used to
create a model with the original MELD variables, but with model coefficients derived
from our data set. (iv) Original MELD was modified with BA and/or non-BA variables,
to test if the performance of original MELD can be improved by adding significant BA
and non-BA parameters from the univariate analysis. First, individual BA and non-BA
variables were analyzed as possible predictors of developing ascites in a univariate
logistic regression analysis.

Then multivariate models were built using backward

elimination regression, where only the most significant variables from the univariate
regression were retained.
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The final multivariate logistic regression models were then validated using
bootstrapping method. Goodness of fit criteria also included the Hosmer-Lemeshow
test, the Akaike information criterion (AIC), and multiple parameters from the receiver
operating characteristic (ROC) analyses.
From univariate logistic regression analysis, total UDCA, total CA, total
MCA, %CDCA, %sulfation, total Mono-OH, % T-amidation, % tri-OH, % non-12α-OH,
and % primary BA significantly increased the odds of having ascites, whereas total
DCA, total HDCA, %LCA, % G-amidation, %mono-OH, and % secondary BA
decreased the odds of having ascites (Table 2.3).
For demographics, univariate logistic regression analysis showed that the odds
of having ascites was significantly 1.3-fold higher in males than females.

For non-BA

parameters, creatinine, INR, protime AST, bilirubin, AST/ALT, and MELD increased
the odds of having ascites, whereas albumin and ALT decreased the odds of having
ascites (Table 2.4).
Using multivariate logistic regression analysis, we have constructed these final
models for ascites prediction:
(i)

The BA variables (BA-OR) model for ascites prediction:
BA score = Log (BA OR) = − 3.463 − (2.452 × %MDCA) + (0.045 × %PrimaryBA )

(ii)

The non-BA variables (non-BA-OR) model for ascites prediction:
g

non − BA score = Log (non BA OR) = 0.947 − (1.205 × Albumin level (dl)) +
(0.189 × MELD)
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(iii)

The original MELD variables (MELD-OR) model for ascites prediction:
original MELD score = Log (MELD OR) = − 4.049 + (0.276 × MELD)

(iv)

The mixed BA and non-BA variables (mixed BA and non-BA-OR) model for
ascites prediction:

mixed BA and non − BA score
= Log (mixed BA and non − BA − OR) = − 0.275 + (0.029 × %CDCA)
− (0.077 ×

PrimaryBA
g
) − (1.143 × Albumin ( ))
SecondaryBA
dl

+ (0.189 × MELD)
Gender was the only significant demographic variable in univariate logistic
regression analysis for all models. However, it was not included in these models
because it resulted in but with no-minimal improvement of model validation criteria
including bootstrapping, AIC, and ROC-AUC (Appendix. Tables A-D). Therefore,
we did not include gender in the multivariate logistic regression model.
Cholestatic diseases are associated with impaired bile flow to the intestine, which
is expected to translate into reduced transformation of primary BA into secondary BA
by intestinal bacteria.

Therefore, an accumulation of primary and a decrease in

secondary BA in the blood may indicate further impairment in bile flow and existing
liver disease [2, 133-136].

This was in agreement with the BA model, where

increasing % Primary BA and decreasing %MDCA (a secondary BA) were the final
significant predictors of liver disease prognosis.

Furthermore, we have previously

demonstrated survival model development for death prediction using cox regression
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analyses.

The same results have shown in their BA model, where increased %CDCA

and %Tri-OH BA (both are primary BA) were the significant predictors of liver disease
prognosis into death.
As shown in Figure 2.1, the probability of developing ascites increased as a
function of BA, non-BA, mixed BA and non-BA original MELD, and original MELD
scores.

In general, logistic regression analysis produces a S-shaped curve, when

predicated probability is plotted against the explanatory score [137].

All four models

produced such S-shaped curves except for the BA score. This is expected in the
absence of extreme values of BA scores from our data set. However, with more
subject enrollment in the future, more extreme BA score values; therefore, S-curve
shape, are expected.
Hosmer–Lemeshow test was one of the criteria to evaluate the goodness of fit
for logistic regression models.

The Hosmer–Lemeshow test results supported the

validity of the BA, non-BA, and mixed BA and non-BA models (P-value >0.05), but not
the original MELD model (Table 2.6). The original MELD model was the only model
with P-value < 0.05, which indicates the expected and observed results were
significantly different.
We also used Akaike information criterion (AIC) to compare the estimated outof-sample prediction error from multivariate logistic regression models.

Minimizing

AIC values represents a good trade-off between goodness of fit vs. degrees of freedom
[128]. The AIC value of the BA, non-BA, and original MELD models were 233.56,
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170.81, and 180.45, which were higher than the AIC value of the mixed BA and nonBA model (167.3) (Table 2.6).
Models were validated using the bootstrapping method (Table 2.7).
Bootstrapping is a resampling technique used to estimate statistics on a population by
sampling a dataset with replacement [130]. Random samples were taken one at a
time, with replacement from our data set to create a series of 1000 new data sets.
Statistics were calculated by comparing these data sets.

In the BA model, the relative

standard error was relatively large because the model parameter (%MDCA) has a high
relative standard error (Appendix. Figure A).
that %MDCA

This could be due to the fact

was not normally distributed in the original data set and because the

sample size was relatively small [138]. Despite the high relative standard error, the
BA model could be considered to pass the bootstrapping validation given the relatively
small sample size of our study.

Overall, the bootstrapping validation results

supported the validity of the BA, non-BA, mixed BA and non-BA, and original MELD
models for ascites prediction.
ROC analysis was used to compare the models for their accuracy to predict liver
patient prognosis into complications such as ascites. The higher the arear under the
ROC curve (AUC), the greater the overall accuracy of the marker in distinguishing
between groups.

For prognostic models, AUC of 0.9 or greater is rarely seen. AUC

between 0.8 and 0.9 indicates excellent accuracy. And any AUC over 0.7 may be
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considered clinically useful [139-141]. Therefore, all four models show high accuracy
for ascites prediction.
ROC analysis was also performed to test sensitivity, specificity, and positive and
negative predictive values (Table 2.6).

The sensitivity is the proportion of true

positive patients (patients who were predicted to have ascites and actually did have
ascites) to the actual positive patient population (total number of patients who actually
did have ascites). The specificity is the proportion of true negative patients (patients
who were predicted not to have ascites and actually did not have ascites) to the actual
negative patient population (total number of patients who actually did not have ascites).
The positive predictive value is the proportion of true positive patients to the total
number of predicted positive patients. The negative predictive value is the proportion
of true negative patients to the total number of predicted negative patients. The high
sensitivity and specificity correspond to the high positive and negative predictive
values, vice versa.

Predictive values are more commonly used than sensitivity and

specificity in clinical studies [137]. The higher positive and negative predictive values
are preferred comparing model performance.

Based on that, we compared positive

and negative predictive values for all four models. The non-BA model has higher
positive and negative predictive values than other models. In addition, the mixed BA
and non-BA model also has high predictive values closed to the non-BA model.
Therefore, both non-BA and mixed BA and non-BA models show better model
performance than others.
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Moreover, ROC analysis was used to determine potential cut-off values which
quantify the normal range of biomarkers. The selection of optimum cut-off values is
a tradeoff between sensitivity vs. specificity, where lower cut-off values are associated
with higher sensitivity but lower specificity, and vice versa.

Scores for the BA, non-

BA, mixed BA and non-BA, and original MELD models were identified as cut-off values
with optimum sensitivity vs. specificity, which were -0.99, -1.18, -1.06, and -1.09
respectively (Table 2.6).

For example, a BA score of -0.99 was considered an

optimum cut-off value in differentiating patients with vs. without ascites because it
maintained a balance between sensitivity (74%) vs. specificity (74%).
These ROC optimum cut-off values were used to split the overall patient
population into two populations for every model. One population contained patients
with model scores higher than the cut-off score and the other contained patients with
model scores lower than the cut-off score.

The p-value of AUCs from the two

populations for every model were then used to find statistically significant differences
(Figure 2.3 and Table 2.8). The p-value of AUCs are smaller than 0.05 and lead to
the rejection of the null hypothesis, indicating AUCs are above the reference line
(AUC=0.5), and vice versa. Only ROC-optimum cut-offs for the BA score (-0.99)
resulted in statistically significant different AUCs based on their p-values; therefore,
they were able to distinguish high- vs. low-score patient populations.
In addition to ascites, we attempted to develop similar models for the prediction of
other

common

liver

disease

complications

including

bacterial

peritonitis,
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encephalopathy, GI bleeding, hepatobiliary carcinoma, hepatorenal syndrome,
jaundice, peripheral edema, and portal hypertension (Appendix. Tables E-H). None
of these complications were as accurately predicted as ascites by any of the BA and
non-BA models. In general, models for the prediction of other complications had
lower sensitivity, lower specificity, lower AUC values, and higher AIC values. This
could be due to the fact that other complications were less common than ascites
(except for portal hypertension and peripheral edema) in our study.

Overall,

improving prediction accuracy would require an increase in the study population to
predict all these other complications.

2.5 Conclusions

We have developed and validated a prognosis model based on BA indices to
predict the development of liver disease complications such as ascites. Other
models, including non-BA, mixed BA and non-BA, and original MELD models, were
also developed to compare their performance with our BA model.

Overall, the

mixed BA and non-BA model was the most accurate based on AIC and ROC
analyses. The mixed BA and non-BA had lower AIC values indicating a smaller
error of distribution and a better trade-off between goodness of fit vs. degrees of
freedom (Table 2.6). Moreover, the mixed BA and non-BA model had the highest
AUC values indicating higher accuracy than other models (Figure 2.2). Therefore,
the mixed BA and non-BA model could be used to predict the development of ascites
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in patients diagnosed with liver-disease at early stages of intervention, such as liver
transplantation.

This will assist in supply allocation and physician decisions when

treating liver diseases.
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2.6 Figures and Tables
Figure 1.1 The chemical structure of major BA and their glycine, taurine, and
sulfate conjugates.
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Figure 2.1 The relationship between the BA, non-BA, mixed BA and non-BA,
and original MELD model scores and the probability of developing ascites.
(b) Non-BA model

Probability of developing ascites

Probability of developing ascites

(a) BA model

BA score

Non-BA score

(d) Original MELD model

Probability of developing ascites

Probability of developing ascites

(c) Mixed BA and Non-BA model

Mixed BA and non-BA score

Original MELD score
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Figure 2.2 Receiver operating characteristics (ROC) curves of the BA, non-BA,
mixed BA and non-BA, and original MELD models for ascites prediction. The
area under the ROC curves (AUC) for (a) BA model, (b) non-BA model, (c) mixed BA
and non-BA model, and (d) original MELD model for differentiating patients with
ascites from patients without ascites.
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Figure 2.3 ROC analysis using optimum cut-off values in BA, non-BA, mixed
BA and non-BA, and original MELD model scores.
(a) BA model
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Table 1.1 Currently used biomarkers for hepatobiliary diseases.

Biomarker

Normal Range

Disease
Hepatocellular injury with any

Aspartate aminotransferase.

cause[141]
8IU/L- 48 IU/L

(AST)

Nonalcoholic fatty liver disease[142]
Primary biliary cirrhosis (PBC)[143]
Hepatocellular injury with any

Alanine aminotransferase

cause[141]
7U/L- 55 U/L

(ALT)

Nonalcoholic fatty liver disease[142]
Primary biliary cirrhosis (PBC)[143]

Gamma-glutamyl transferase.

Biliary or pancreatic disease[141]
8U/L- 61 U/L

(GGT)

Primary biliary cirrhosis (PBC)[143]
Cholestatic liver disease[141]

Alkaline phosphatase (ALP)

40U/L-129U/L
Primary biliary cirrhosis (PBC)[143]
Nephrotic syndrome[141]

Albumin

3.5-5.0 g/dL
Cirrhosis[144]
Hepatitis C

Total proteins

6.3-7.9 g/dL
Alcoholic fatty liver disease[145]
Cirrhosis

Total bilirubin

0.3-1 mg/dL
Nonalcoholic fatty liver disease[142]
Cirrhosis

Unconjugated bilirubin

0.2-0.8 mg/dL
Nonalcoholic fatty liver disease[142]
Cirrhosis

Conjugated bilirubin

0.1-0.3 mg/dL
Nonalcoholic fatty liver disease[142]
Hepatocellular carcinoma

Lactate dehydrogenase (LD)

122-222 U/L
Acute liver failure (ALF)[146]
Prolonged in liver disease
9.4-12.5

Prothrombin time (PT)

,Pancreatic
seconds
insufficiency[141];Cirrhosis[147]

International normalized ratio

Cirrhosis[148]; Non‐alcoholic fatty
~1.1

(INR)

liver disease[149]
0.84-1.21
Nonalcoholic fatty liver disease[150]

Serum creatinine

milligrams
Hepatobiliary diseases [2]
per deciliter

56

Table1.2 Summary of models/scores/criteria for prediction of hepatobiliary
disease prognosis
Models, Scores or Criteria

Disease

Outcomes

Study
population

Body composition-MELD (BC-MELD) =

Cirrhosis with

LTM

173 patients

MELD score+3.59*skeletal muscle mass

liver

(male, 97;

index (SM)I+5.42*high intramuscular

transplantation

female 76) as

adipose tissue content (IMAC)+2.06*high

acute liver

visceral-to-subcutaneous adipose tissue

failure as the

area ratio (VSR).[151]

indication for LT.

Risk score=0.002*Carbohydrate Antigen

Atypical bile

The model for

Total 375

19-9 ((CA-199) +0.072*Age-6.612d[152]

duct

predicting

patients. The

hyperplasia

atypical

atypical

hyperplasia in

hyperplasia

the

group 36

intrahepatic

patients (man,15

bile duct

and women,21).

Normal
range
NA

NA

The non-atypical
hyperplasia
group 339
patients (93
males, 246
female)
HBV-ACLF MELD (HAM) model= 0.174*

Hepatitis B

STM

A total of 530

MELD + 1.106 * hepatic encephalopathy

virus related

HBV-ACLF

(HE) -(0.003*alpha-fetoprotein(AFP))+

acute-on-

patients. training

(0.237*white blood cell (WBC)) + (0.103

chronic liver

cohort (300

*Age) - 11.388[153]

failure (HBV-

patients) and

ACLF)

validation cohort

NA

(230 patients)
Risk score = 3.090 + 0.035 *Age (years) -

Acute

The

754 patients with

Score >

0.050 *PTA (%) + 0.005 * TBIL (mmol/L) +

deterioration

verification

AD of HBV-

-2.12

0.044 *D/T (%) - 0.072 * Na (mmol/L) +

(AD) of

and

related CLD,

(higher

0.180 * HBV DNA (log10IU/mL) [154]

hepatitis B

evaluation the

training cohort

survival

virus (HBV)-

new

(580 patients)

rate)

related chronic

prediction

and a validation

Score

liver disease

model

cohort (174

<-2.12

(CLD)

patients)

(lower
survival
rate)
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ABIDE model= [2.003*INR+

Non-alcoholic

LTM related

512 patients in

The high

0.824*AST/ALT ratio + 0.821*(Type 2

fatty liver

to liver

derivation

score ≥

diabetes:0 if absent, 1 if present) +

disease

cirrhosis in

cohort, 299

4.1

0.806*(esophageal varices: 0 if absent, 1 if

(NAFLD)

NAFLD

patients with

The low

patients

compensated

model

cirrhosis 244 of

score <4.1

present) + 0.332 *total bilirubin.[155]

346 in validation
cohorts
Chronic Liver Failure Consortium (CLIF)-C

Acute-on-

Acute-on-chronic liver failure (ACLF)
score= 10 x (0.33 *CLIF-C OF + 0.04 *

STM

A total 177

The score

chronic liver

patients with

≤ 39 with a

failure (ACLF)

Acute-on-

higher

chronic liver

survival

failure (ACLF),

rate. The

age + 0.63 * Ln [leukocyte count] -2)[156]

Male (132)

score ≥ 51

Female (45)

with a
lower
survival
rate.

The age-bilirubin-international normalized

Acute-on-

ratio-creatinine (ABIC) score = (age *0.1)

STM

A 398 total

The score

chronic

patients

> 9.44

+ (serum bilirubin * 0.08) + (serum

hepatitis B liver

diagnosed with

creatine * 0.3) +(INR * 0.8)[157]

failure (HBV-

HBV-ACLF, a

shorter

ACLF)

training cohort of

survival

305 patients and

time.

a validation

The score

cohort of 93

≤ 9.44 had

patients

longer

With

survival

The Platelets- albumin-bilirubin (PALBI)

Cirrhosis

Prognostic

A total 195

PALBI

score = (2.02*log10 bilirubin) +(-

indicator of

patients,127

score:

0.37*(log10 bilirubin)2) +(-0.04 *albumin)

mortality

male, 68

grade 1

+(-3.48*log10 platelets) +(1.01* (log10

Female, median

(score ≤-

platelets)[158]

age 66 years

2.53),
grade 2
(>-2.52 to
-2.09), and
grade 3
(>-2.09)
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The albumin- bilirubin (ALBI) score = 0:66

Decompensate

× log10 bilirubin (μmol/l) − 0.085 × albumin

d cirrhosis

STM

A total 456

NA

patients with

(g/l) [159]

DeCi, The
median age
53.5, Male(302),
Female (154)

ICGR15-MELD model= 0.117 × ICGR15 +

Early allograft

0.128 × MELD score − 3.446.[160]

dysfunction
(EAD) and

The

A total 87

The score

accuracy of

consecutive liver

≥0.098

model

transplant

(66.7% of

early

patients, a

EAD

postoperative

training cohort

incidence).

complications

(n=61) and an

The

after LT

internal
validation cohort
(n=26)

score<
0.098
(6.5% of
EAD
incidence)

CLIF Consortium Acute Decompensation

Chronic Liver

scores (CLIF-C ACLF) =

Failure

STM

A total 209
patients with

10×[0.03×Age(year) + 0.66×Ln

ACLF and 1245

(Creatinine(mg/dL)) + 1.71×Ln (INR) +

patients without

0.88×Ln (WBC (10^9 cells/L)) - 0.05 ×

ACLF (Chronic

Sodium(mmol/L)+8[161]

Liver Failure)

Lille Model and MELD Score=

[2.4778 *

Alcoholic

(Lille model - 0.4114) + 0.0695 * (MELD –

hepatitis

24.6812)] * 0.9836

NA

STM

A total of 712

NA

patients. 67

[162]

patients from the
derivation data
set and 108
patients from the
validation data
set from 8
pooled cohort
studies.

Lille Model and Maddrey DF score= S =

Alcoholic

2.5373 * (Lille model - 0.4195) + 0.0095 *

hepatitis

(Maddrey’s DF - 61.8519)] * 0.9850[162]

STM

A total of 712
patients. 67
patients from the
derivation data
set and 108
patients from the
validation data
set from 8

NA

59

pooled cohort
studies.
Lille Model and ABIC Score= S = 2.3260 *

Alcoholic

(Lille model - 0.4114) + 0.2362 * (ABIC -

hepatitis

STM

A total of 712

NA

patients. 67

8.3882)] *0.980[162]

patients from the
derivation data
set and 108
patients from the
validation data
set from 8
pooled cohort
studies.

Modified CTP score, Second modified

Cirrhosis

The

A total 30,897

CTP score, and creatinine-modified CTP

transplant-

cirrhotic patients

core (Ascites, Encephalopathy, Serum

free survival

with at least 5

bilirubin, Albumin and INR)[163]

in.

years of follow-

NA

up, (72.3 %)
male (97.2 %)
cirrhotic patients
King's College criteria (KCC) (The grade of

Acute liver

hepatic encephalopathy, arterial blood pH,

Failure

STM

100 consecutive

NA

patients with

prothrombin time, and serum

acetaminophen-

creatinine)[164]

induced ALF

APACHE II score = acute

Acute-on-

STM

100 patients

physiology score + age points + chronic

chronic liver

were enrolled in

health points[116]

failure

the study,

NA

including 87
males and 13
females, with a
median age of
49 years
The sequential organ failure assessment

Paracetamol-

Comparing

A total of 138

(SOFA) score (PaO2/FiO2 (mmHg),

induced acute

prognostic

patients (61

Plateletsx 103/mm, Bilirubin (mg/dl)

liver injury

accuracy on

males, 77

Glasgow Coma Sore. Creatinine, (mg/dl),

both modified

female). 125

hypotension (yes or no))[165]

MELD and

were classified

SOFA score

as ‘nonparacetamol’
cases, and 123
patients had
taken a
staggered

NA

60

paracetamol
overdose.
MESO=[MELD/Na (mmol/L)] +100

iMELD=MELD+[age(years)*0.3]-

Paracetamol-

Comparing

A total of 138

induced acute

prognostic

patients (61

liver injury

accuracy on

males, 77

both modified

female). 125

MELD and

were classified

SOFA score

as ‘non-

[0.7*Na(mmol/L] +100,

UKELD=5*(1.5*ln(INR)+0.3*ln(creatinine(u
lmol/L)+0.6*ln(bilirubin(lmol/L)-

paracetamol’

13*ln(mmol/L)+70 [165]

cases, and 123

NA

patients had
taken a
staggered
paracetamol
overdose.
MDF (Maddrey’s discriminant function)

Alcoholic

=4.6(prothrombin time -control time) +

hepatitis

STM

A total 66

NA

patients with

serum bilirubin [in µmol/L]/17.1[166]

alcoholic
hepatitis

The Glasgow alcoholic hepatitis score

Alcoholic

(GAHS)[167]

hepatitis

STM

A total 241

The

patients with

score<9

alcoholic

(high

hepatitis

survival
rate)
The
score
≥9(lowe
r survival
rate)

Beclere model = (0.0484 × [Age in Years]

Alcoholic

+ 0.469 × [encephalopathy] + 0.537 ×

hepatitis

STM

A total 183

NA

patients enrolled

Loge [Bilirubin in μmol/L] - 0.052 ×

in the study

[Albumin in g/L] [168]
The Alcoholic Hepatitis Histologic Score

Alcoholic

(AHHS)

hepatitis

STM

A Total 121

low

patients

morality

(Stage of fibrosis, Bilirubinostasis,

admitted to the

(0-3

Neutrophil infiltration,

Liver Unit in

points)

Megamitochondria)[169]

Spain, and a
total 205

Moderate

patients from 5

morality

academic

(4-5

centers in the

points).

61

United States

High

and Europe

morality
(6-9
points)

TAP score = 100 × (exp [lr]/ 1 + exp [lr];

Alcoholic

The severity

Note lr = −3.71 + (0.34*TMA) -

Hepatitis

of patients

patients, 43

≥36 with

with Alcoholic

healthy subjects

high

Hepatitis

without liver

mortality

(0.087*Pentane) [170]

A total of 80

The score

disease
The CLIF-SOFA score (Bilirubin, Cerebral

Acute-on-

STM and

A total 1349

failure, INR, mean arterial pressure, partial

chronic liver

LTM

patients with

pressure of arterial oxygen/fraction of

failure

NA

ACLF

inspired oxygen)[171]
GLOBE score = 0.044378 * age at start of

Primary biliary

UDCA therapy + 0.93982 * LN(bilirubin

cirrhosis

The

4119 patients

transplant-

with PBC treated

times the upper limit of normal [ULN] at 1

free survival

with

year follow-up)+0.335648*LN(alkaline

for patients

ursodeoxycholic

phosphatase times the ULN at 1 year

with PBC

acid in European

follow-up) - 2.266708 * albumin level times

and North

the lower limit of normal (LLN) at 1 year

American

follow-up)- 0.002581 * platelet count per

countries

NA

109/L at 1 year follow- up + 1.216865[172]
UK-PBC Risk Scores [173]

Primary biliary

LTM

cirrhosis
Rochester I Criteria: ALP 2* ULN (upper

Primary Biliary

limit of normal)[174]

Cholangitis

4,099 patients

NA

with PBC
LTM

A total 180

NA

patients, who we
continue to
follow with PBC.

Paris I Criteria: ALP 3× ULN; AST 2× ULN;

Primary Biliary

and TB 1 mg/dL [174]

Cholangitis

LTM

A total 292

NA

patients with
PBC

Rotterdam Criteria: TB <1× ULN and

Primary Biliary

albumin >1× LLN[174]

Cholangitis

LTM

A total 375

NA

patients with
PBC and
median followup time was 9.7
years

Toronto Criteria: ALP 1.67× ULN[174]

Primary Biliary

LTM

Cholangitis

A total 69

NA

Patients with
PBC

Paris II Criteria: ALP 1.5× ULN; AST 1.5×

Primary Biliary

ULN; and TB 1 mg/dL[174]

Cholangitis

LTM

A total165
patients with

NA
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early-stage PBC
followed up for
an average 7
years
UDCA: Albumin(,38g/L) , Histologic stage (

Primary Biliary

>3), Lack of biochemical response at 1

Cholangitis

LTM

A total 192

NA

patients with

year.[175]

PBC

Glasgow alcoholic hepatitis score (GAHS):

Alcoholic

STM and

A total 274

Age, Leukocytes, Urea, PT (prothrombin)

hepatitis

LTM

patients with

ratio, Bilirubin[176]

NA

alcoholic
hepatitis

Lille model= exp(R)/(1 + exp(-R); R=

Alcoholic

3.19–0.101 * (age in years) + 0.147 *

hepatitis

STM

A total 274

NA

patients with

(albumin day 0 in g/L) + 0.0165 * (bilirubin

alcoholic

day 0 - bilirubin day 7 (mmol/l)) - 0.206 *

hepatitis

(renal insufficiency) - 0.0065 * (bilirubin
day 0 in mmol/l)- 0.0096

(PT in

seconds)[176]
MELD-Na score= MELD + 1.59 * (135-

Alcoholic

Na), with maximum and minimum Na of

hepatitis

STM

A total 274

NA

patients with

135 and 120 mEq/L [176]

alcoholic
hepatitis

Mayo model = 0.871 log. (bilirubin in

Primary Biliary

mg/dl) +-2.53 1og (albumin in gm/dl)

Cirrhosis

LTM

A total 106 Mayo

NA

Clinic primary

+0.039* age in years +2.38 log.

biliary cirrhosis

(prothrombin time in sec) +0.859

patients

edema[177]
The Nutritional Index (CONUT) [178]

End-Stage

LTM

A total 58

Liver Diseases

patients with

(ELD)

end-stage liver

NA

diseases
Prognostic nutritional indices (Onodera:

End-Stage

LTM

A total 58

PNI-O) = 10Albumin + 0.005(total

Liver Diseases

patients with

lymphocyte count))[178]

(ELD)

end-stage liver

NA

diseases
Actin-free Gc-globulin combine with King's

Acute liver

college hospital criteria [179]

failure (ALF)

STM

A total of 252
patients with
varying
etiologies from
the U.S. ALF
Study Group

NA
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Clichy’s Criteria (Factor V, age, and the

Fulminant

presence of grade 3-4

hepatic failure

consecutive

encephalopathy)[180]

(FHF)

patients with

STM

A total 120

NA

FHF, adults (n =
64) and children
(n = 56)
End-Stage Liver Disease (PELD) =

Fulminant

STM

4.80*[Ln serum bilirubin (mg/dL)] +

hepatic failure

consecutive

18.57*[Ln INR] - 6.87*[Ln albumin (g/dL)] +

(FHF)

patients with

4.36*(year old) + 6.67*(growth failure)[180]

A total 120

NA

FHF, adults (n =
64) and children
(n = 56)

London Criteria (muscle fatigability or

Acute liver

weakness presence of symptoms

failure

STM

A total 61

NA

patients had

including the brain and centra nervous

fulminant liver

system, autonomic dysfunction, fluctuation

failure

of symptoms)[181]
Hangzhou Criteria (Total tumor diameter

Hepatocellular

less than or equal to 8 cm, Total tumor

Carcinoma

LTM

A total 195

NA

patients with

diameter more than 8 cm, with

HCC were

histopathologic grade I or II and

retrospectively

preoperative AFP level less than or equal

analyzed and

to 400 ng/mL)[182]

various clinical
and pathological
factors

logit(P)=-4.595+0.824×fibrinogen

Hepatocellular

concentration (g/L) + 0.641 × AFP score

Carcinoma

LTM

A total of 119

The score

patients

< -0.85

1 for AFP<=20ng/ml,

receiving liver

with

2 for 20<AFP<=100ng/ml,

transplantation

better

3 for100<AFP<=200ng/ml,

for

outcome

4 for 200<AFP<=400ng/ml,

43hepatocellular

The score

5 for AFP>400ng/ml )[183]

carcinoma

> -0.85
with less
outcome

Milan Criteria (Single tumor less than 5 cm

Hepatocellular

in size, no more than three tumors, all less

Carcinoma

than 3 cm in diameter)[184]

LTM

A total 195
patients with
HCC were
retrospectively
analyzed and
various clinical
and pathological
factors

NA

64

UCSF criteria (1 tumor ≤6.5 cm or ≤3

Liver

tumors with the largest tumor diameter

transplantation

patients

≤4.5 cm and total tumor diameter ≤8

(OLT) for

underwent OLT

cm)[185]

patients with

for HCC during

hepatocellular

the study period

LTM

A total of 3,434

NA

cancer (HCC)
Radiomics score=2.688195- 4.306105e-

Solitary

09× (Contrast_0) + 7.882485e-08×

LTM

A total of 319

Rad

hepatocellular

solitary HCC

score>4.3

(Cluster Prominence_0) + 3.492191×

carcinoma

patients

2 with high

(Information measure of correlation2_0) +

(HCC)

mortality

3.088437× (Inverse difference normalized

Rad

(INN)-0)-2.511158× (Information measure

score≤

of correlation2_2)-1.641851×

4.32 with

(Energy_2.5)[186]

low
mortality

Barcelona Criteria (ALP)[174]

Primary Biliary

LTM

Cholangitis

A total 292

NA

patients with
PBC

MELD-XI score = 5.11 * ln (serum

End-Stage

STM and

A total 2,939

bilirubin) + 11.76 * ln (serum creatinine) +

Liver Disease

LTM

patients met the

9.44 [187]

in pediatric

NA

inclusion criteria

patients
undergoing
orthotopic heart
transplant
Adam's score

(Age, Presence of

Non colorectal,

Prediction of

A total 78

Low score

extrahepatic metastases; Major hepatic

non-

survival rate

consecutive

(0-3)

resection, R2 resection DFI, Primary tumor

neuroendocrine

patients with

Medium

type)[188]

(NCNN) liver

NCNN liver

score (4-

metastases

metastases

6); High
score (710)

ALFSG prediction model= Logit SS= 2.67

Acute liver

– 0.95(HE*)+1.56(Etiology*)-

failure

LTM

A total 1974

NA

patients who

1.25(Vasopressor Use*) - 0.70 (ln bilirubin)

met criteria for

- 1.35 (ln INR)[189]

ALF

NAFLD fibrosis score = -1.675 + 0.037 *

Non-alcoholic

The liver-

A total 646

NAFLD

Age (yrs)+0.094*BMI(kg/m2)+1.13 *

fatty liver

related

biopsy proven

score<-

IFG/diabetes (Yes=1, No=0) + 0.99 *

disease

mortality

NAFLD patients

1.45 (Low)

AST/ALT ratio-0.013 * Platelet (10^9/L) -

(NAFLD)

0.66 *Albumin (g/dl)[190]

NAFLD
score>0.6
7(High)
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FIB-4 index= Age (yrs) * AST

Non-alcoholic

The liver-

A total 832

FIB-4

[U/L]/(Platelet [10^9/L] * (ALT

fatty liver

related

patients with

index<1.3(

[U/L]^1/2)[190]

disease

mortality

NAFLD

Low); FIB-

(NAFLD)

4
index>3.2
5(High)

BARD score (AST/ALT ratio> 0.8=2

Non-alcoholic

The liver-

A total 827

points; BMI>28=1 point; Presence of

fatty liver

related

patients with

diabetes= 1points; Score range from 0 to 4

disease

mortality

NAFLD

points)[190]

(NAFLD)

APRI score (AST to Platelet Ratio Index).

Non-alcoholic

The liver-

A total 236

(AST [IU/L])/(AST upper limit of normal

fatty liver

related

patients fulfilled

[IU/L])/(Platelet [10^9/L])[190]

disease

mortality

in this study

NA

NA

(NAFLD)
Hepascore = exp [-4.185818 - (0.0249 *

Non-alcoholic

The liver-

A total 510

Age) + (0.7464* SEX) + (1.0039*a2

fatty liver

related

patients with

macroglobulin) + (0.0302*Hyaluronic

disease

mortality

hepatitis B or C

acid)+(0.0691 Bilirubin) -

(NAFLD)

NA

and matched on

(0.0012*GGT)][190]

fibrosis stage
were included

FORNs score=7.811 -3.131ln (platelet

Chronic

The liver-

The cohort study

FORNs

count) +0.781ln(GGT)+3.467ln(age)-

Hepatitis C

related

included 502

score

0.014(cholesterol)[191]

Patients

mortality

consecutive

<4.21 and

Without

patients with

>6.9with

Hepatic

chronic hepatitis

significant

Fibrosis

C.

fibrosis.

BARDI score (improved BRAD score by

Advanced liver

The liver-

A total 107

adding INR)[192]

fibrosis in

related

patients with

nonalcoholic

mortality

biopsy proven

Frailty index=(-0.33*gender- adjusted grip

fatty liver

NAFLD were

disease

enrolled.

Cirrhosis

The liver-

A total 536

strength)+(-2.529*number of chair stands

related

patients enrolled

per second)+(-0.04* balance time)+6[193]

mortality

in the study

NA

NA

The donor risk index (DRI) (Age, COD

Nonalcoholic

The liver-

A total 20023

Donor risk

(cause of death), DCD (donation after

fatty liver

related

transplants,

index

cardiac death), Partial/Split, race, regional/

disease

mortality

using livers from

national share, height, CIT (cold ischemia

deceased

time)[194]

donors

(≤1.1or
>1.5)

The balance of risk (BAR) score (MELD

End-stage liver

The mortality

A total 233

BAR

score, cold ischemia time, recipient age,

disease

and

patients

score>18

donor age, previous liver transplantation,

(higher

66

and life support at the time of

posttransplant

survival

transplant)[195]

outcome

rates)
BAR≤18
(lower
survival
rates).

ADOPT-LC score (score range from 0-8)

Cirrhosis

The in-

A total 2197

(Age CTP class (A, B, C), Charleston

hospital

patients are

comorbidity index, Duration of anesthesia

mortality

involved in this

(<180, 181-420, >420))[196]

NA

study.

Model for Early Allograft Function Scoring

Early allograft

(MEAF)[197]

dysfunction

STM

A study

NA

including 1026
consecutive liver
transplants
patients was
performed for
MEAF score
development

ALF in-hospital mortality score (ALFIHMS)

Acute liver

The in-

55 individuals

ALFIHMS

= 0.714 + 0.02 (total bilirubin) + 0.03

failure (ALF)

hospital

with ALF were

score>15

mortality

included in the

with 50%

study.

higher in-

(APACHE II score) × 10[198]

hospital
mortality.
Note: STM and LTM represents the short-term mortality and long-term mortality.
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Table 2.1 List of BA indices.

Composition

Hepatic

Intestinal

Hydrophilicity

CYP8B1 Activity

Total Mono-OH

Total 12α-OH

Total Primary

% of individual BA Total G-amidated

Total Di-OH

Total non-12α-OH

Total Secondary

Total T-amidated

Total Tri-OH

% Sulfation

% Mono-OH

CA/ CDCA

% Primary

% Amidation

% Di-OH

% 12α-OH

% Secondary

% G-amidation

% Tri-OH

% non-12α-OH

% T-amidation

HI

Concentration of
individual BA

Metabolism
Total Sulfated

Contribution

12α-OH/ non12α-OH Primary/ Secondary
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Table 2.2 Demographics.
Total Patients(N)

257
Gender

Male

136

Female

121
Age (years)

Mean ± SEM

52.2 ± 0.71
Body Mass Index (BMI)

Mean ± SEM

30.7 ± 0.45
Race

White

217

Black
217
Asian

11
103
7

Hispanic

4

Others

18
Liver disease complications

Ascites

62

Bacterial peritonitis

2

Encephalopathy

36

GI bleeding

18

Hepatobiliary carcinoma

15

Hepatorenal syndrome

1

Jaundice

7

Peripheral edema

63

Portal hypertension

106
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Table 2.3 Univariate logistic regression analyses for the prediction of
developing ascites in the entire liver-patient population based on BA indices.
BA (µM) / BA indices
Total BA
Total LCA
Total UDCA
Total CDCA
Total DCA
Total HDCA
Total MDCA
Total CA
Total MCA
Total HCA
% LCA
% UDCA
% CDCA
% DCA
% HDCA
% MDCA
% CA
% MCA
% HCA
Total Unamidated
Total G-amidated
Total T-amidated
% Amidation
% G-amidation
% T-amidation
Total Unsulfated
Total Sulfated
% Sulfation
Total Mono-OH
Total Di-OH
Total Tri-OH
% Mono-OH
% Di-OH
% Tri-OH
Total 12α-OH
Total non-12α-OH
12α-OH/ non12αCA/
CDCA
OH
% 12α-OH
% non-12α-OH
Total Primary
Total Secondary
Primary/ Secondary
% Primary
% Secondary
HI

B-value (Regression
Coefficient)
0.002
0.024
0.001
0.009
-0.001
-20.099
-20.104
0.052
0.008
0.407
-0.071
-0.049
0.048
-0.061
-6.66
-3.281
0.065
-0.007
-0.671
0.016
0.002
0.019
0.041
-0.004
0.037
0.061
0.002
0.012
0.024
0.002
0.018
-0.071
0.018
0.021
0.008
0.002
-0.787
-0.997
-0.033
0.033
0.007
0.001
0.09
0.049
-0.049
0.074

P-value
0.059
0.275
0.538
0.002
0.871
1.000
0.999
0.007
0.528
0.012
0.004
0.000
0.000
0.000
0.108
0.003
0.005
0.713
0.001
0.076
0.103
0.016
0.017
0.665
0.002
0.076
0.061
0.338
0.275
0.074
0.029
0.004
0.095
0.108
0.162
0.068
0.114
0.159
0.014
0.014
0.003
0.543
0.001
0.000
0.000
0.012

Odds ratio (OR): Exp (B)
1 unit

10%

20%

1.002
change
1.024
1.001
1.009
0.999
0.000
0.000
1.053
1.008
1.502
0.931
0.952
1.049
0.941
0.001
0.038
1.067
0.993
0.511
1.016
1.002
1.019
1.042
0.996
1.038
1.016
1.002
1.012
1.024
1.002
1.018
0.931
1.018
1.021
1.008
1.002
0.455
0.369
0.968
1.034
1.007
1.001
1.094
1.050
0.952
1.077

1.010
change
1.007
1.002
1.017
0.999
0.980
0.923
1.013
1.002
1.007
0.936
0.892
1.178
0.908
0.980
0.880
1.040
0.996
0.977
1.009
1.008
1.011
1.433
0.970
1.039
1.009
1.009
1.106
1.007
1.008
1.010
0.936
1.142
1.027
1.007
1.008
0.974
0.974
0.928
1.291
1.017
1.003
1.020
1.258
0.770
0.999

1.020
change
1.013
1.004
1.034
0.999
0.961
0.851
1.027
1.005
1.015
0.877
0.795
1.387
0.825
0.960
0.774
1.081
0.991
0.954
1.017
1.017
1.021
2.054
0.940
1.080
1.017
1.018
1.224
1.013
1.017
1.021
0.877
1.304
1.055
1.014
1.017
0.948
0.949
0.861
1.666
1.034
1.005
1.041
1.582
0.594
0.998

BA concentrations are in (µM), while BA indices are in percentage. HI is hydrophobicity index.
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Table 2.4 Univariate logistic regression analyses for the prediction of
developing ascites in the entire liver-patient population based on
demographics and non-BA parameters
Demographics and.

B-value

P-value

Non-BA parameters
Age(year)

0.012

0.366

BMI

-0.008

Gender
Race

Odds ratio (OR): Exp (B)
1 unit

10%

20%

0.685

1.012
change
0.992

1.000
change
1.000

1.001
change
0.999

1.291

0.000

3.636

*

0.258

*

Creatinine (mg/dL)

0.048

0.601

1.049

1.005

1.010

Albumin (g/dL)

-1.980

0.000

0.138

0.481

0.231

INR

1.529

0.000

4.614

1.180

1.391

Protime (sec)

0.133

0.000

1.142

1.156

1.337

AST (U/L)

0.003

0.168

1.003

1.017

1.034

NA

NA

*

*

ALT (U/L)

-0.004

0.257

0.996

0.977

0.955

Bilirubin (mg/dL)

0.536

0.000

1.709

1.069

1.142

AST/ALT

1.895

0.000

6.653

1.246

1.552

MELD

0.276

0.000

1.318

1.281

1.642

B-value: regression coefficient. *Race is a categorical variable which contain five race groups. There are five values
for B-value and OR, one for each race group, which are not shown, because was not statistically significant in
univariate logistic regression analysis. NA: Not applicable.
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Table 2.5 Multivariate logistic regression analyses for ascites in the entire liverpatient population.
(a) BA model
BA

B-value (Regression

Standard

Parameters

Coefficient)

Error

Intercept

-3.463

-

% MDCA

-2.452

% PrimaryBA

0.045

P-value

Odds ratio (OR): Exp (B)
1-unit

10%

20%

0.000

change
0.031

change
-

change
-

1.112%

0.027

0.086

0.909

0.826

0.008%

0.000

1.046

1.234

1.524

Using the regression coefficients from this table, the estimated (OR) of developing ascites by the BA model is:

BA score=Log (BA-OR)= -3.463-(2.452 ×% MDCA) +(0.045 ×% Primary BA)

(b) Non-BA model
Non-BA

B-value (Regression

Standard

P-value

Odds ratio (OR) : Exp (B)

Error

1-unit

10%

20%

parameters

Coefficient)

Intercept

0.947

-

0.560

change
2.577

change
-

change
-

MELD

0.189

0.050

0.000

1.208

1.185

1.404

Albumin level

-1.205

0.387

0.002

0.300

0.640

0.410

Using the regression coefficients from this table, the estimated (OR) of developing ascites by the Non-BA model is:

non-BA score=Log (Non-BA-OR) = 0.947+ (0.189 × MELD) -(1.205 × albumin level)

(c) Mixed BA and Non-BA model
Mixed BA and non-BA

B-value

Standard

P-value

parameters

(Regression

Error

Intercept

Coefficient)
-0.275

1.768

0.894

% CDCA

0.029

0.012%

PrimaryBA/SecondaryBA

-0.077

Albumin
level
A BA
MELD

-1.143
0.189

Odds ratio (OR): Exp (B)
1-unit

10%

20%

0.014

chang
0.79
e
1.029

chang
e
1.104

chang
e
1.218

0.032

0.015

0.926

0.983

0.967

0.407

0.004

0.319

0.655

0.429

0.053

0.000

1.208

1.185

1.404

Using the regression coefficients from this table, the estimated (OR) of developing ascites by the mixed BA and nonBA model is

mixed BA and non-BA score=Log (BA-OR) = -0.275+(0.029×%CDCA) –
(0.077×Primary BA/Secondary BA) - (1.143 × Albumin level) + (0.189 × MELD)

(d) Original MELD model
MELD

B-value (Regression

Parameters

Standard

P-value

Odds ratio (OR): Exp (B)
1-unit

10%

20%

Coefficient)

Error

Intercept

-4.049

0.554

0.000

change
1.317

change
-

change
-

MELD

0.276

0.045

0.000

0.017

0.026

0.001

Using the regression coefficients276
from this table, the estimated (OR) of developing ascites by the original MELD
model is:

original MELD score= Log (MELD-OR) = -4.049+ (0.276 × MELD)
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Table 2.6 Model comparisons for ascites prediction.
(a) BA model
ROC Analysis
SEN

SPE

33.90%

88.30%

PPV
48.80%

NPV
80.20%

Cutoff value (SEN, SPE)
-0.99 (74%, 74%)

HL(P-value)

AIC value

0.168

223.56

HL(P-value)

AIC value

0.228

170.81

HL(P-value)

AIC value

0.11

167.3

HL(P-value)

AIC value

0.029

180.45

(b) Non-BA model
ROC Analysis
SEN

SPE

56.40%

91.50%

PPV
72.10%

NPV
84.30%

Cutoff value (SEN, SPE)
-1.18 (78%, 78%)

(c) Mixed BA and Non-BA model
ROC Analysis
SEN

SPE

PPV

NPV

54.50%

90.10%

68.2%

83.60%

Cutoff value (SEN, SPE)
-1.06 (78%, 78%)

(d) Original MELD model
ROC Analysis
SEN

SPE

45.50%

91.50%

PPV
67.60%

NPV
81.30%

Cutoff value (SEN, SPE)
-1.09 (76%, 76%)

SEN (sensitivity), SPE (specificity), PPV (positive predictive value), NPV (negative predictive value). P-value is for
the Hosmer-Lemeshow test (HL).

AIC is Akaike information criterion.
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Table 2.7 Bootstrapping validation for ascites predication models.
Variables

B-value

Bias

SE

RSE

p-value

95% CI
Lower

Upper

BA model
Intercept

-3.463

-0.049

0.548

-

0.001

-4.666

-2.445

% MDCA

-2.452

-0.192

0.948%

296.3%

0.002

-4.823

-1.148

% PrimaryBA

0.045

-0.049

0.008%

0.02%

0.001

0.032

0.061

Non-BA model

%

Intercept

0.947

-0.056

1.702

-

0.554

-2.606

4.139

MELD

0.189

0.009

0.062

0.59%

0.001

0.086

0.325

Albumin_level

-1.205

-0.014

0.389

11.21%

0.001

-2.028

-0.490

Intercept

-0.236

-0.052

2.029

-

0.897

-4.572

3.484

% CDCA

0.029

-0.002

0.013%

0.03%

0.013

-0.001

0.052

Primary/Secondary

-0.077

0.012

0.055

1.58%

0.028

-0.164

0.053

Albumin
(g/dL)
BA
MELD

-1.158

-0.023

0.46

13.26%

0.005

-2.108

-0.219

0.189

0.016

0.066

%0.63%
Original MELD model

0.003

0.087

0.341

Intercept

-4.049

-0.098

0.658

-

0.001

0.183

0.411

MELD

0.276

0.007

0.061

0.59%

0.001

-5.573

-2.996

Mixed BA and non-BA model

B-value (Regression Coefficient). SE (Standard Error). RSE (Relative standard
Error).
.

Interval).

CI (Confidence
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Table 2.8 ROC analysis using optimum cut-off values.

Cutoff

AUC

P-value

SE

95% CI
Lower

Upper

BA score
High BA score<-0.99

0.842

0.00

0.05

0.752

0.932

Low BA score≥-0.99

0.527

0.65

0.06

0.41

0.644

0.806

0.00

0.05

0.707

0.905

0.670

0.01

0.07

0.538

0.801

Non-BA score
High non-BA score<-1.18
Low non-BA score≥-1.18

Mixed BA and non-BA score
High BA and non-BA score<-1.06

0.895

0.00

0.04

0.821

0.970

Low BA and non-BA score≥-1.06

0.672

0.01

0.06

0.546

0.797

Original MELD score
High original MELD score<-1.09

0.879

0.00

0.04

0.809

0.949

Low original MELD score≥-1.09

0.657

0.01

0.06

0.532

0.782

AUC is the area under the ROC curve. SE (Standard Error).

CI (Confidence Interval).
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Appendix
Figure A. Histograms for the BA, non-BA, mixed BA and non-BA, and original
MELD model’s variables.
(a) BA model’s variables
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Table A. Bootstrapping validation for ascites predication models with gender.

Variables

B-value

Bias

SE

RSE

p-value

95% CI
Lower

Upper

BA model
Intercept

-4.057

-

-

-

-

-

-

% MDCA

-2.568

-0.201

1.07%

334.4%

0.009

-5.309

-1.096

% PrimaryBA

0.044

0.001

0.008%

0.02%

0.001

0.03

0.062

Gender

1.121

0.023

0.404

76.2%

0.003

0.387

1.996

Intercept

0.385

-

-

-

-

-

-

Non-BA model
MELD

0.180

0.016

0.065

0.62%

0.003

0.086

0.347

Albumin_level

-1.248

-0.023

0.409

11.57%

0.001

-2.131

-0.480

Gender

1.213

0.011

0.482

91.0%

0.004

0.368

2.263

Intercept

-0.54

-

-

-

-

-

-

Mixed BA and non-BA model
0.025

-0.001

0.014%

0.04%

0.026

-0.003

0.052

Primary/Secondary

% CDCA

-0.068

0.006

0.054

1.7%

0.042

-0.159

0.059

Albumin
BA(g/dL)
MELD

-1.230

-0.03

0.438

12.4%

0.002

-2.151

-0.438

0.181

0.019

0.064

0.61%

0.003

0.084

0.327

Gender

1.127

0.056

0.528

99.6%

0.01

0.224

2.322

Original MELD model
Intercept

-4.696

-

-

-

-

-

-

MELD

0.270

0.014

0.064

0.61%

0.001

0.180

0.425

Gender

1.083

0.043

0.446

84.1%

0.011

0.294

2.070

B-value (Regression Coefficient). SE (Standard Error). RSE (Relative standard Error).

Interval).

CI (Confidence
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Table B. Model comparison for ascites prediction with gender.
The BA model with gender
AUC value

AIC value

0.833

215.63

The non-BA model with gender
AUC value

AIC value

0.872

164.15

The mixed BA and non-BA model with gender
AUC value

AIC value

0.878

160.8

The original MELD model with gender
AUC value

AIC value

0.855

175.29

AUC is the area under the ROC curve. AIC is Akaike information criterion.

78

Table C. Other models for ascites prediction.
Other Models

Logistic(P)

Bootstrapping(P)

HL(P)

AUC

AIC value

NA

NA

0.859

171

0.865

171

MELD variables with coefficients from our data set
Creatinine

0.739

NA

INR

0.155

NA

Bilirubin

0.000

NA

NA

Original MELD modified with BA variables
MELD
%PrimaryBA

0

0.002

0.009

0.005

0.037

Original MELD modified with non-BA variables
MELD

0.000

0.001

Albumin level

0.002

0.001

0.228

Original MELD modified with BA and non-BA variables
%CDCA

0.014

0.013

Primary/SecondaryBA

0.015

0.028

Albumin level

0.005

0.005

MELD

0.000

0.003

(P) is P-value.

NA: Not applicable.

not significant (P-value > 0.05).
AIC is Akaike information criterion.

0.11

0.875

167

Bootstrapping was not performed because P-values of model parameters were

HL is the Hosmer–Lemeshow test. AUC is the area under the ROC curve.
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Table D. Other models for ascites prediction with gender.

Other Models

Logistic(P)

Bootstrapping(P)

HL(P)

AUC

AIC value

MELD variables with coefficients from our data set
Creatinine

0.537

NA

INR

0.091

NA

Bilirubin

0.000

NA

0.002

NA

Gender

NA

NA

NA

0.862

171

0.870

165

Original MELD modified with BA variables
MELD

0.000

0.001

%PrimaryBA

0.017

0.025

0.02

0.021

Gender

0.043

Original MELD modified with non-BA variables
MELD

0.000

0.003

Albumin level

0.001

0.001

Gender

0.006

0.008

0.706

Original MELD modified with BA and non-BA variables
%CDCA

0.031

0.026

Primary/SecondaryBA

0.032

0.042

Albumin level

0.003

0.002

0.001
0.003
0.013

0.003

MELD
Gender
(P) is P-value.

NA: Not applicable.

not significant (P-value > 0.05).
AIC is Akaike information criterion.

0.145

0.878

161

0.01

Bootstrapping was not performed because P-values of model parameters were

HL is the Hosmer–Lemeshow test. AUC is the area under the ROC curve.
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Table E. Prediction of other liver disease complications using BA models.
ROC Analysis
Other

SEN

SPE

PPV

NPV

AUC

B(P)

HL(P)

AIC value

Bacterial peritonitis

0%

100%

0%

99.2%

0.952

0.001

0.967

22.39

Encephalopathy

2.8%

98.1%

20.0%

85.7%

0.777

0.001

0.744

177.75

GI bleeding

0%

100%

0%

92.8%

0.791

0.001

0.027

112.81

Hepatobiliary

0%

100%

0%

94%

0.745

0.001

0.714

104.52

NA

NA

NA

NA

NA

NA

NA

NA

Jaundice

14.3%

100%

100%

97.6%

0.867

0.001

0.218

55.22

Peripheral edema

17.5%

98.80%

64.7%

77.7%

0.710

0.553

0.418

262.89

Portal hypertension

63.2%

82.6%

72.8%

75.3%

0.813

0.001

0.480

266.10

Complications

carcinoma
Hepatorenal
syndrome

SEN (sensitivity), SPE (specificity), PPV (positive predictive value), NPV (negative predictive value).
Hosmer–Lemeshow test.

HL is the

AUC is the area under the ROC curve. B(p) is the P value for Bootstrapping method.

AIC is Akaike information criterion.

NA: Not applicable.
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Table F. Prediction of other liver disease complications using non-BA models.
ROC Analysis
Other

SEN

SPE

PPV

NPV

AUC

B(P)

HL(P)

AIC value

Complications
Bacterial peritonitis

NA

NA

NA

NA

NA

NA

NA

NA

Encephalopathy

24.2%

97.0%

61.5%

86.4%

0.829

0.001

0.140

145.28

GI bleeding

0.0%

100.0%

0.0%

92.9%

0.762

0.001

0.588

105.72

Hepatobiliary

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

Jaundice

25.0%

99.1%

50.0%

97.3%

0.961

0.001

0.967

43.63

Peripheral edema

38.6%

90.7%

59.5%

80.7%

0.839

0.003

0.225

193.34

Portal hypertension

67.4%

82.2%

78.0%

72.8%

0.818

0.005

0.251

213.17

carcinoma
Hepatorenal
syndrome

SEN (sensitivity), SPE (specificity), PPV (positive predictive value), NPV (negative predictive value).
Hosmer–Lemeshow test.

HL is the

AUC is the area under the ROC curve. B(p) is the P value for Bootstrapping method.

AIC is Akaike information criterion.

NA: Not applicable.
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Table G. Prediction of other liver disease complications using mixed BA and
non-BA models.
ROC Analysis
Other

SEN

SPE

PPV

NPV

AUC

B(P)

HL(P)

AIC value

Bacterial peritonitis

0.0%

100.0%

0.0%

99.2%

0.952

0.004

0.967

22.39

Encephalopathy

24.2%

86.4%

61.5%

86.4%

0.829

0.001

0.14

145.28

GI bleeding

0.0%

100%

0.0%

92.8%

0.809

0.008

0.886

111.72

Hepatobiliary

0.0%

100%

0.0%

94.0%

0.717

0.001

0.703

107.07

NA

NA

NA

NA

NA

NA

NA

NA

Jaundice

NA

NA

NA

NA

NA

NA

NA

NA

Peripheral edema

50.9%

91.9%

69.0%

84.1%

0.857

0.352

0.694

188.06

Portal hypertension

67.7%

87.4%

80.7%

77.6%

0.858

0.006

0.09

223.88

Complications

carcinoma
Hepatorenal
syndrome

SEN (sensitivity), SPE (specificity), PPV (positive predictive value), NPV (negative predictive value).
Hosmer–Lemeshow test.

HL is the

AUC is the area under the ROC curve. B(p) is the P value for Bootstrapping method.

AIC is Akaike information criterion.

NA: Not applicable.
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Table H. Prediction of other liver disease complications using original MELD
models.
ROC Analysis
Other

SEN

SPE

PPV

NPV

AUC

B(P)

HL(P)

AIC value

Bacterial peritonitis

NA

NA

NA

NA

NA

NA

NA

NA

Encephalopathy

24.2%

97.0%

61.5%

86.4%

0.829

0.001

0.14

145.28

GI bleeding

27.1%

90.5%

75.9%

52.8%

0.684

0.001

0.72

108.07

Hepatobiliary

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

Jaundice

90.9%

91.0%

75.9%

97.0%

0.939

0.001

0.799

43.9

Peripheral edema

28.1%

93.6%

64.0%

76.2%

0.778

0.001

0.279

207.81

Portal hypertension

63.2%

81.4%

75.9%

70.3%

0.818

0.001

0.022

221.49

Complications

carcinoma
Hepatorenal
syndrome

SEN (sensitivity), SPE (specificity), PPV (positive predictive value), NPV (negative predictive value).
Hosmer–Lemeshow test.

HL is the

AUC is the area under the ROC curve. B(p) is the P value for Bootstrapping method.

AIC is Akaike information criterion.

NA: Not applicable.
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